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ABSTRACT 
Type 2 diabetes affect large population and able to develop micro and macrovascular complicati
ons. There are many non- genetic and genetic factors or both are associated for the occurrence of 
type 2 diabetes mellitus (T2DM) and diabetic complications. Genes of the renin angiotensin syst
em angiotensin converting enzyme insertion/deletion gene polymorphism has been associated wi
th the risk of type 2 diabetes and its complications. The aim of the present study was to 
investigate the association of angiotensin converting enzyme gene polymorphism, risk of type 2 
diabetes and its complications. A total of 222 subjects (111 T2DM and 111 healthy controls) 
were collected from Bahir Dar Felegehiwot referral hospital and Bahir Dar town, respectively by 
using non-probability purposive sampling techniques. Patients with T2DM were selected using 
non probability purposive sampling technique. Minidray fully automated analyzer was used for 
biochemical tests such as glucose, total cholesterol, triglycerol, urea and creatinine to assess the 
associated risk factors. The ACE I/D genotypes were identified by Polymerase chain reaction 
(PCR) using appropriate primers and PCR reaction conditions. The present study revealed that 
the frequency of DD genotype and D allele were higher in type 2 diabetes mellitus compared to 
healthy controls (DD, 64.2% Vs 35.6% P < 0 .001) and ( D, 79.3% Vs 59.9% P < 0.001). DD 
genotype showed three fold increase risk towards T2DM as compared to II Genotype (OR: 
2.984, CI: 1.332 - 6.689, P < 0.02). The D allele carriers had five times high risk of getting 
diabetic as compared to I allele. (OR, D 2.178; CI: 1.168 – 3.232 P < 0.001 Vs I OR, 0.459; CI: 
0.309 – 0.681 P < 0.001). To determine whether ACE gene polymorphism was associated with 
diabetic complication, patients with type 2 diabetes were divided into diabetic hypertension, 
diabetic retinopathy and diabetic nephropathy. The frequency of ACE DD genotype and D allele 
in patients with diabetic hypertension were significantly higher than T2DM patients (41.6% and 
60.4% Vs 19.5% and 37.8% P < 0.01). The frequency of ACE DD genotype and D allele in 
patients with diabetic retinopathy were also higher than T2DM patients (28.6% and 44.1% Vs 
19.5% and 37.8%). The frequency of ACE genotype in patients with diabetic nephropathy did 
not show significant association. This might be due to small sample size that lack statistical 
power. This study indicated that the frequency of ACE DD genotype and D allele were markedly 
higher in patients with type 2 diabetes. This genotype and allele were significantly associated 
with diabetic hypertension and diabetic retinopathy patients. 
Keywords: ACE gene polymorphism; diabetes complications; diabetic hypertension; diabetic 
retinopathy; diabetic nephropathy 
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1. INTRODUCTION 
Diabetes is a rising global health burden, which is a multifactorial, heterogeneous group of 
metabolic disorder with the common feature characterized by a deficiency or failure in 
maintaining normal glucose homeostasis; this is due to defective insulin secretion, resistance 
insulin action or  due to  a combination of both (Karuna et al., 2013). 
Diabetes mellitus is a serious condition with potentially stressful complications that affects all 
age groups worldwide (Guariguata et al., 2013). The American Diabetes Association (ADA) 
divides diabetes mellitus into four categories (Kleinberger & Pollin, 2015). Type 2 diabetes 
mellitus (T2DM) is the second category and most diabetes is sorted in this category, a 
heterogeneous group of disorders caused by some combination of insulin resistance and 
impairment of insulin secretion (Kleinberger & Pollin, 2015). Insulin resistance is a condition in 
which the body’s muscle, fat and liver cells does  not use insulin effectively leads to high 
concentration of glucose in the circulation and occurred when the body can no longer produce 
enough insulin to compensate for the impaired ability to use insulin  ( Kaku,  2010; Skarfors et 
al., 1991 and Colditz et al., 1990).  
According to reports by International diabetic federation (IDF), in 2013 approximately 382 
million people had diabetes globally and the IDF has estimated this number will rise to  592 
million by 2035 (Guariguata et al., 2013). Among those type 2 diabetes, accounts about 350 
million people worldwide and estimated 10 percent of the world’s adult population (nearly 600 
million people) will suffer from the disease by 2035 (Colagiuri et al., 2015).  However, the 
largest increase of population with diabetes occur in sub-Saharan Africa, with a projected growth 
of 19.8 million in 2013 to 41.5 million by 2035 (Guariguata et al., 2013). Among this, over 90%  
are type 2  diabetes in Sub-Saharan Africa (Hall et al., 2011). This is due to a rapid uncontrolled 
urbanization, lifestyle changes towards western diets, reduced quality of food, late diagnosis, 
inadequate screening and diagnostic resources, poor control of blood sugar level, inadequate 
treatment at an early stage and smoking in sub-Saharan Africa (Kengne et al., 2013; Mbanya et 
al., 2010 and Vivian et al., 2010). Since 1985 Ethiopia has been a member of IDF and the IDF 
estimated the number of diabetic among adults (20-79 years) in 2010 was 2.5% and the number 
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is expected to rise in to 3.5% by the year 2030 (Shaw et al., 2010 ). Currently diabetes is a 
serious challenge in Ethiopia ( Worku, 2010; Abera, 2000 and kasper and Lester, 1988). 
Individuals who are unaware of diabetics disorder (Chronic hyperglycemia of diabetes) are at 
very high risk of chronic complications (Mbanya et al., 2010). The complication may be 
macrovascular or microvascular origin and risk for diabetic hypertension. Macrovascular such as 
cardiovascular disease (CVD), coronary heart disease, peripheral vascular disease and 
cerebrovascular disease and  microvascular complications such as, affecting the eyes cause of 
blindness (diabetic retinopathy), end stage renal disease (ESRD or diabetic nephropathy), 
diabetic foot and nerves (diabetic neuropathy (Tesfaye & Gill, 2011; Al-Khawlani et al., 2010 
and Michael, 2008). The macro and microvascular complication of diabetes mellitus is also 
common in Ethiopia ( Gebrekirstos et al., 2015 and Tesfaye et al., 2015).  
It is typically a multifactorial disease, there are many factors associated in the occurrence T2DM 
and the progress of its complication. Risk factors such as obesity (Body mass index (BMI)), over 
eating, stress as well as aging, dyslipidemia, hypertension, smoking, physical inactivity, dietary 
patterns, family history, and specific genes are the most frequently known risk factors for T2DM 
(Lyssenko et al., 2008; Valdes et al., 2007 and Holt, 2004). However, the genetic factors (genetic 
origins) of T2DM and its complication are not obviously understood because the genetics of 
T2DM is polygenic and multifactorial origins as a result of the interaction between the 
environment and multiple genes ( Vivian et al., 2010 and Strojek et al., 1997).  
At present many candidate genes have been associated with T2DM (Lyssenko et al., 2007). 
However, genes that are encoding for the renin-angiotensin system (RAS) are the main genetic 
risk factors for T2DM and the progress of its complications (Giacchetti et al.,2005 and Jacobsen 
et al., 2003 ). Among genes involved in the RAS, Angiotensin converting enzyme (ACE) gene 
encoding is a key enzyme. This gene is located at chromosome 17q23 consisting of 26 exons, 25 
introns and it spans 21 kb (Erdos, 1990). The polymorphism of ACE gene due to the insertion (I) 
or deletion (D) of a 287 bp Alu repeat sequence near the 3′ end of intron 16 leads to three 
genotypes DD, II and ID (  Skipworth et al., 2011; Rivera et al., 2004 and Rigat et al., 1990). 
The main function  of this gene is the conversion of Angiotensin I to vasoactive, natriuretic 
octapeptide angiotensin II in liver (Erdos, 1990) and inactivates a vasodilator peptide bradykinin 
(Kuoppala et al., 2000). Alleles of ACE gene polymorphism are present in both healthy 
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individuals and T2DM patients with different frequencies and DD genotype individuals are at 
risk of T2DM and its complications (Jeffers  et al., 1997). This implies that, imbalances in RAS 
functions are related to insulin resistance and susceptible to T2DM. The present state of 
knowledge about ACE gene polymorphism in T2DM and its complication have a doubt because 
there were some studies in the literature that described a null association between the etiologies 
of T2DM and its complication with ACE gene polymorphism (Skipworth et al., 2011and 
Jacobsen et al., 2003). However, most of the reported literature has indicated  that ACE gene 
polymorphism is associated with T2DM and its complication in different populations ( Hussein 
et al., 2015; Nikzamir et al., 2006; Yang et al., 2006 and Yoshida et al., 1996 ).   
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1.1 Statement of the Problem 
Diabetes is a rising global health problem both in developed and developing continents, 
especially in Africa, sub-Saharan Africa due to late diagnosis, inadequate screening and lack of 
diagnostic resources, poor control of blood sugar, and inadequate treatment at an early stage of 
the disease ( Guariguata et al., 2013, Kengne et al., 2013 and Sleire 2011). In Ethiopia, 
undiagnosed cases (late diagnosis) is highest proportion (82.6%) among the rural population and 
63% among the urban population and family history of diabetes is highly associated with 
diabetes mellitus (Abebe et al., 2014). This indicates that proper awareness of the public about 
the disease early diagnosis is not a practice as a result new cases already have diabetes with 
hypertension and other complication at the time of diagnosis ( Seifu  et al., 2015 and Abebe et 
al., 2014). Genetic polymorphism could be indicators for risk of T2DM and can serve as a 
marker so that may help for protecting the disease with better treatment out come and early 
diagnosis even before the onset of the disease. The role of ACE gene polymorphism in the 
pathogenesis of type 2 diabetes and its impact on the progress of diabetic complication has been 
investigated by different studies. However, there were no reported data of ACE gene 
polymorphism on the risk of T2DM and diabetic complications among the Ethiopian population. 
Therefore, the aim of this study was to investigate the association of risk factors, ACE gene 
polymorphism in patients with type 2 diabetes and its complications in the Ethiopian population, 
Bahir Dar Felegehiwot Referral Hospital.  
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1.2 Significance of the Study 
 
Type 2 diabetes is a complex disorder resulting from an interaction between multiple genes and 
environmental factors. As a result, this study was conducted on both socio- demographic risk 
factors and one of the associate genes (ACE). It is important to look for the gene association in 
the Ethiopian population and compare it with previous studies on the same issue other than 
Ethiopian population. This will help scientists and physicians to rationalize research priorities 
regarding T2DM and its complication serve as a marker for early diagnosis of the disease and to 
order better therapeutic drugs that help to reduce the occurrences of diabetic complications. In 
addition, the result of this study would be used as a source of information to the community and 
health care professionals. Policymakers also get ideas about gene polymorphisms to develop 
policies and strategies for evidence-based approaches to a better treatment individual medicine 
for type 2 diabetes and its complications.  
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2. OBJECTIVES 
2.1 General Objective 
 
The general objective of this study was to assess the association of angiotensin converting 
enzyme gene polymorphism wit risk of diabetes 2 and its complication among patients visiting 
Bahir Dar Felegehiwot referral hospital. 
2.2 Specific Objectives  
 
The specific objectives of this study were  
 To compare the frequency of ACE gene polymorphism in type 2 diabetes mellitus 
patients and healthy controls 
 To evaluate the frequency of ACE gene polymorphism in patients with type 2 
diabetes without complications and diabetic complications 
 To determine the correlation of ACE gene polymorphism to risk of diabetic type 2 
and degree of complications   
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3. LITERATURE REVIEW 
3.1  Epidemiology of Type II Diabetes 
 
Type 2 diabetes is mostly characterized due to insulin resistance and beta cell dysfunction (Kahn, 
2003). Insulin resistance is a condition in which cells do not respond to the normal action of 
insulin secreted from the pancreatic β-cells. Consequently, cellular uptake of glucose does not 
occur and blood glucose level become elevated (Kahn, 2003).  
Type 2 diabetes is also called non-insulin-dependent diabetes (NIDDM), the most common type 
of diabetes mellitus worldwide and it is a challenge both in the developed and developing 
countries (Colagiuri et al., 2015; Mbanya et al., 2010 and Dahiru et al., 2008). The other report 
by King et al., (1998) indicated that the number of T2DM in 2000 was estimated approximately 
150 million individuals with the disease and this number is expected to double by 2025 (King et 
al., 1998). Similar report also indicated that T2DM represents 90% of the overall burden of 
diabetes worldwide with approximately 150 million cases (Diamond, 2003).  Diabetic forum on 
2015 indicate that, T2DM affects about 350 million people worldwide and if the tendency 
continues, an expected 10 percent of the world’s adult population (nearly 600 million people) 
will suffer from the disease by 2035 (Colagiuri et al., 2015).  
The prevalence of T2DM in Africa was mostly lower than 1%, except in South Africa (0·6–
3·6%) and Coted’Ivoire (5·7%) between the 1960s and early 1980s (McLarty et al., 1990). 
However, this disorder is currently the most common sub-Saharan Africa, which is reported by 
Colagiuri et al (2015) and Hall et al (2011), over 90% of T2DM are in Sub-Saharan Africa 
having population prevalence ranged from 1% in rural Uganda to 12% in urban Kenya ( 
Colagiuri et al., 2015 and Hall et al., 2011).  
Type 2 diabetes is also common in Ethiopia (Worku, 2010 and Abera, 2000). According to the 
2011 report of the International Diabetes Federation (IDF), the figure of adults living with 
diabetes in Ethiopia was 3.5% (Whiting et al., 2011). Among those, Mekelle Ayder referral 
hospital, reported that, most of the patients, 216/263 (82%), had T2DM while 47/263 (18%) of 
them suffered from type I diabetes (T1DM), which indicates T2DM is common in Ethiopia 
(Ambachew et al., 2015). The new report from 2011-2014 at Dilla referral hospital also reveal 
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that T2DM were highly predominated diseases across the year than T1DM (Alemu, 2015). The 
other study by Worku et al (2010) in the southwest Ethiopia of Jimma university specialized 
hospital indicate that, the larger proportion of 189 (62.0%) patients had T2DM and most of them 
are acute complications (Worku et al., 2010). However, the study by Brown et al (1998) in the 
northern Ethiopia,  university of  Gondar teaching referral hospital reveal that , T1DM are more 
common than T2DM which accounts 40% of the town  and 75% of rural patients (Brown et al., 
1998). On the other hand, the study in another time in the northern Ethiopia,  university of  
Gondar teaching referral hospital reveal that T2DM account 71% urban areas and 23% in the 
rural areas (Alemu & Watkins, 2004). T2DM is the fourth or fifth leading cause of death in most 
developed countries and the growing evidence indicate that, it has reached epidemic proportions 
in many developing counties like Ethiopia (Amos et al., 1997). 
3.2  Insulin and its Resistance in Type 2 Diabetes 
 
The pancreas islets of langerhans consist of insulin-releasing beta cells, glucagon-releasing 
alpha-cells, somatostatin-producing delta-cells, and pancreatic polypeptide-producing cells 
(Elayat et al., 1995). Of these, insulin attempts to maintain normoglycaemia through a constant 
supply of glucose between meals and conversion of the excess glucose to glycogen 
(glycogenesis) in the liver and muscles (Taylor and Agius 1988). Glucagon has the reveres 
action of insulin it converts liver glycogen to glucose (glycogenolysis) and muscle tissue 
glycogen into pyruvic acid or lactic acid in anaerobic conditions, which later changed to glucose 
in the liver (Taylor and Agius, 1988). 
The insulin receptor (IR) is a heterotetramer consisting of two α and two β subunits those are 
linked by disulphide bonds (White and Kahn, 1994 and White et al., 1988).  β subunit has a 
hydrophobic transmembrane region, and an intracellular domain which has several tyrosine 
residues, a tyrosine kinase and an ATP-binding site (White et al., 1988). Insulin binding to the α 
subunits activates β subunit tyrosine protein kinase and brings phosphorylation of tyrosine 
residues and  activation of the β subunit kinase leads to transmission of the insulin signal, 
perhaps by initiating a phosphorylation/dephosphorylation cascade (White et al., 1988 and 
Denton et al., 1981). The alteration in the insulin-receptor tyrosine kinase activity induced by 
cyclic AMP-dependent protein kinase phosphorylation of serine residue of the receptor sites (β 
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subunit), and this could faithfully underlie catecholamine-induced insulin resistance (Tanti et al., 
1987). During the situation of extreme insulin resistance and T2DM, the process of signal 
transmission from the insulin receptor, a subunit insulin-binding site to activate the kinase 
appears to be defective at one or more sites (Caro et al., 1986). This leads to amino acid 
substitution in the ATP-binding region or the tyrosine kinase region and diminishes insulin 
action (Ellis et al., 1986). This impaired insulin secretion through a dysfunction of pancreatic β-
cell and impair insulin action through insulin resistance are the main pathologic defect of type 2 
diabetes (Holt, 2004). 
3.3  Complications of Type 2 Diabetes and Diabetic Hypertension 
 
The complications of T2DM are macro and microvascular origin. Macrovascular such as 
cardiovascular disease (CVD), coronary heart disease, peripheral vascular disease and 
cerebrovascular disease and  microvascular complications such as, affecting the eyes cause of 
blindness (diabetic retinopathy), end stage renal disease (ESRD or diabetic nephropathy), 
diabetic foot and nerves (diabetic neuropathy (Tesfaye & Gill, 2011; Al-Khawlani et al., 2010 
and Michael, 2008). Among those complications, microvascular complication is frequently 
occurred in T2DM. As a result, this study has paid great attention for diabetic nephropathy, 
diabetic retinopathy and diabetes with hypertension.  
3.3.1  Diabetic Nephropathy 
 
Diabetic nephropathy (DN)  is a common and severe complication that leading  the cause of 
chronic kidney disease in patients with T2DM and in a lesser proportion of subjects with T1DM 
(Wang et al., 2008). However, the survival rate of T2DM patients with renal failure is much 
worse than that of patients with renal failure resulting from T1DM or other causes (Mogensen, 
2003). In addition, T2DM occurs more frequently at a younger age and these individuals live 
longer with diabetes which expected to develop diabetic renal disease and ESRD due to a late 
complication (after 15 to 25 yr)  (Mogensen, 2003).  
Diabetic nephropathy is characterized by macro albuminuria >300 mg in a 24-hour urine or 
macro albuminuria and abnormal renal function as represented by an abnormality in serum 
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creatinine and serum urea and evidenced a decline in glomerular filtration rate (GFR) (Fontela et 
al., 2014 and Shlomo et al., 2011). The progression of diabetes mellitus to DN monitored by 
serum urea and creatinine level, those are simple biomarkers available for nephropathy 
individuals and are higher in the diabetics especially in the case of DN (Bamanikar et al., 2016). 
Males had elevated urea and creatinine levels compared to females, also age and period on 
treatment are associated with impairment of renal function in both sexes (Mafuratidze et al., 
2014). The other study also indicates that age and plasma creatinine had a positive correlation 
(Amartey et al., 2015). 
T2DM is characterized by hyperfiltration in the early stages but GFR values has decreasing when 
duration of diabetes increased with a mean GFR 103.508 ± 33.369 ml/min which indicates the 
progress of diabetic nephropathy (Agarwal et al., 2005). Similar study also indicated that longer 
duration of diabetes and lower diastolic blood pressure are associated with reduced estimated 
glomerular filtration rate (eGFR) among 2368 subjects with T2DM had 12% of eGFR 
<60ml/min/1.73m2 (Wall et al., 2010). Glomerular filtration rates below 60 mL/min/1.73m² 
represents a decrease of approximately 50% in normal renal function and leads to complications 
of chronic kidney disease (CKD) (Fontela et al., 2014). The other report can classify renal failure 
in to different stages based on eGFR as Normal or high >90, mildly decreased 60-89, mildly to 
moderately reduced 45-59, moderately to severely declined 30-44, severely decreased 15-29 and 
Kidney failure <15 (KDIGO, 2013). 
3.3.2  Diabetic Retinopathy 
Diabetic retinopathy (DR) is a leading cause of visual impairment among diabetic patients. Some 
new diagnosis patients with T2DM have DR, which indicates there is a need for early screening 
of all type 2 DM patients (Jammal et al., 2013). Among 10 individuals, one of them has at risk 
for DR (Hu et al., 2015). Age at diagnosis, high total cholesterol, high low-density lipoprotein, 
triglycerides, microalbuminuria, elevated blood pressure, the use of anti-hypertensive drugs, 
cigarette smoking and duration of hypertension are associated risk factor for the development of 
DR (Hussain et al., 2013; Shammari et al., 2005 and Ohn et al., 1993). However, the study in 
China indicates that among the above risk factors only diabetic duration is the risk for the 
occurrence of DR (Hu et al., 2015). 
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Diabetes is one of the risk factor for retinopathy and other serious diseases in the Bangladesh 
population (Islam et al., 2015). The study in the northern part of Ethiopia, diabetic clinic at 
Mekelle Hospital indicate that among 105 diabetic patients 21% of them had diabetic retinopathy 
(Gill et al., 2008). The other review reports in Gondar University referral hospital indicated that 
the prevalence of DR among Ethiopian diabetics has been estimated to be approximately 25% 
(Nigatu, 2012). 
3.3.3  Diabetic with Hypertensive 
Hypertension is not classified as micro or macrovascular complication rather it is a risk factor for 
diabetes mellitus patients (Reaven, 1988). Cellular insulin resistance is responsible for the 
development of hypertension through alteration substrate supply or energy needs of the cell and 
the resultant changes in substrate/energy requirements sensitize, either directly or by altering ion 
fluxes into the cell, the vascular smooth muscle response to  amines such as nor epinephrine and 
Angiotensin II  (DeFronzo & Ferrannini, 1991). The other study also recommended that, 
microvascular dysfunction may affect both peripheral vascular resistance that leads to 
hypertension (Serne et al., 1999) and insulin-mediated glucose disposal that leads to insulin 
resistance (Clark et al., 2003; Serné et al., 2001and Serne et al., 1999).  
Individual who had a systolic blood pressure of 140mmHg and/or diastolic blood pressure of 90 
mmHg considered to have hypertension. The studies reveal that systolic and diastolic blood 
pressure were risk factors for type 2 diabetes and diabetic complications (Unnikrishnan et al., 
2007).  
3.4  Risk Factors for type 2 diabetes and its complications 
 
There are many risk factors for T2DM and it’s progression towards diabetic complications. 
Those risk factors can be non-genetic or genetic etiology or either of both (Kasper  et al., 2004). 
Among the non-genetic or either of both risk factors most of the studies showed that, the 
association of type 2 diabetic patients and its complication with advancing age and duration of 
diabetes, obesity, poor glycemic control, smoking, gender, lipids, hypertension, proteinuria, 
serum creatinine, eGFR, urea, higher BMI (Viswanathan et al., 2012; Haque et al., 2010 and 
Iranparvar et al., 2006 ).  
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Many of the studies show that, there are many genes associated for the occurrence of T2DM and 
the progress of diabetic complications. Among the genetic risk factors, researcher  addresses by 
family studies, and other genes such as genes in the rennin Angiotensin system, genes associated 
to dyslipidemia, hypertension and oxidative stress are confirmed as a genetic risk factors 
contribute for the occurrence of T2DM and the development diabetic complications both in 
T2DM and T1DM (Al-rubeaan et al., 2014; Giacchetti et al., 2005 and White et al., 1998).  
3.4.1 Non-genetic Risk Factors 
3.4.1.1  Smoking 
Numerous prospective studies has been  reported that current smokers are having a risk factor for 
developing of T2DM ( Hur et al., 2007; Sairenchi et al., 2004 and Hu et al., 2001). The other 
studies reveal that, the association between smoking and T2DM has stronger among heavy 
smokers (more than 20 cigarettes/day ) compared with light smokers ( Willi et al., 2007 and 
Patja et al., 2005). In addition, the follow-up study found that an increased risk of type 2 diabetes 
is occur in the first 2-3 years after smoking termination (Yeh et al.,2010 and Sairenchi et 
al.,2004). 
 In diabetes mellitus, numerous prospective studies found that cigarette smoking is able to 
increases the risk of microvascular and macrovascular complications such as in diabetic 
retinopathy smoking raises the risk of changes in the blood vessels inside the eye that can cause 
blindness in those patients over the age of 65 (Thornton et al., 2005). Cigarette smoking has its 
own effects on lipid profile such as triglyceride, cholesterol and low-density lipoprotein (LDL) 
levels are high in smoker individuals but high-density lipoprotein is lower in smokers than in 
non-smokers (Craig et al., 1989). 
3.4.1.2  Age and Sex 
Age and sex are globally identified risk factors for diabetes mellitus (Ebenezer et al., 2003). 
Individual who have an older age (>45) are having a chance to develop hyperglycemia and it is 
more critical in women than men (Veghari et al., 2010). The other similar report in Libya also 
indicate that, subjects having ≥50 years of age had nearly double risk of complications than those 
with <50 years of age (Roaeid and Kadiki. 2011). The report in Nigeria indicates that age was 
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associated with T2DM in both sexes (Ekpenyong et al., 2012). However, the recent study in 
Batticaloa district, Sri Lanka indicate that age above 50 years have more chance to develop 
diabetes than other age groups but not correlated with gender (Prasanth et al., 2015). The other 
study reported that, male genders are more prevalent in the high-risk group for T2DM (Marinho 
et al., 2013). The study in Bangladesh indicate that sex is not associated with T2DM, however 
individuals in the middle (31-50 years) and older age group (>50 years) are exposed to the 
occurrence of T2DM (Al Sharmin and Munima, 2016). 
 Diabetes tends to increase with increasing age (high in 40-59 years) has triple risks of 
developing T2DM than younger ages (Whiting et al., 2011). The other report also supporting 
these idea, diabetes tends to increase with increasing age (high in 41-60 years) and tend to 
decrease in >60 years for both men and women (Ruhembe et al., 2014). Increasing in age is 
associated with higher risk of T2DM without difference regarding to gender (Bhalerao et al., 
2014). Most of subjects with diabetes are age between 40 and 59 years and the mean age did not 
differ according to gender (Sagna et al., 2014).  
Many studies have a conflict in the association or non-association between gender and diabetic 
complications. To solve this conflict some of the studies reveal that, gender has no any impact on 
progression of renal disease or survival (Hall et al., 2011 and Mogensen, 2003). However, other 
studies showed that males having an independent risk factor or have strong association with 
diabetic nephropathy and the risk of developing diabetic nephropathy is 20 times higher 
compared to female (Ahmad et al., 2014; Al-rubeaan et al., 2014 and Abdulhakeem et al., 2012). 
This implies that male is having an increased risk for diabetic and renal disease than females. 
The other study in diabetic retinopathy also shows that male genders are high risk for the 
development of diabetic retinopathy (Hussain et al., 2013). However, the other report reveals 
that female genders are at high risk for the development of diabetic retinopathy (Ohn et al., 
1993).  
3.4.1.3  Duration of Diabetics 
Diabetes duration mean that the survival of patient long time with diabetics. Such cases were 
studied by different researchers and some of the studies reveal that, patients with duration of 
diabetes of 7-14 and ≥14 years had nearly twofold and threefold increase in complications than 
14 
 
patients with duration of <7 years (Roaeid and Kadiki, 2011). Patients that have been diagnosed 
for the disease for more than 10 years having complications are higher than diagnosis of the 
disease for less than 10 years (Cortez et al., 2015).   These imply that longer diabetes duration is 
the cause for the development of micro or macrovascular diabetic complication.  
In microvascular complication, diabetic nephropathy  (diabetes duration of 15 years) (Al-rubeaan 
et al., 2014 and Kasper et al., 2004). The other study also reveal that diabetic nephropathy is 
associated with a longer diabetic duration (Mafuratidze et al., 2014 and Unnikrishnan et al., 
2007). Diabetic retinopathy increased with the duration of diabetes mellitus (5-10 yr: 5.2- fold; > 
10 yr: 10-fold) (Kim et al., 2011).   Diabetic duration is also associated with retinopathy (EL-
Shazly et al., 2011 and Correa et al., 2003).  With the mean duration of diabetes mellitus in all 
patients (13.35 ± 8.17 years) diabetic retinopathy is highest in women (11.91 ± 7.92 years) than 
in men (14.42 ± 8.20 years)  (El-Babb et al., 2012).   
3.4.1.4  Body Mass Index 
Obesity and T2DM are worldwide public health problem in the 21st century that increase the 
prevalence of diabetes parallels that of obesity. Obesity is excess storage of fat in the body that 
leads to the development of cardiovascular morbidity, insulin resistance by muscle cells and 
resistance to the cellular actions of insulin which results the occurrence of T2DM and (Hribal et 
al., 2002). This an impaired ability of insulin inhibits glucose output from the liver and promote 
glucose uptake in fat and muscle cell is due to adipose tissue releases increased amounts of 
glycerol, hormones, non-esterified fatty acids, pro-inflammatory cytokines and other factors  
associated to the development of insulin resistance (Hribal et al., 2002 and Saltiel and Kahn, 
2001).  
Many studies have reported that increased BMI is a strong risk factor for T2DM   (Almdal et al., 
2008 and Knowler et al., 1991). This occurs both in men ( Almdal et al., 2008 and Knowler et 
al.,1991) and women ( Colditz et al., 1990). Genes responsible for obesity and insulin resistance 
interact with environmental factors such as increased fat/ calorie intake and decreased physical 
activity resulting in the development of obesity and insulin resistance followed ultimately by the 
development of T2DM ( Kahn et al.,2006 and O'Rahilly et al.,2006). Those obese individuals 
having elevated plasma levels of free fatty acids are known to cause muscle insulin resistance 
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(Yaturu, 2011). People with severe obesity are at greater risk of T2DM than obese people with a 
lower BMI calculated as the weight in kilograms divided by the height in meters squared ( 
Gatineau  et al., 2014 and Iranparvar  et al., 2006). BMI is long-term predictors of renal function 
in men than in women anthropometric and metabolic parameters are less predictive eGFR (Nagel 
et al., 2013).  
3.4.1.5  Dyslipidemia 
Resistance to insulin has a direct link to the changes in lipid profiles in NIDDM, by developing  
a number of alterations in lipid metabolism and lipoprotein composition that make more 
pathogenic in patients with T2DM and usually it is associated with higher concentrations of 
Triglycerol (TG) and lower concentrations of high- density lipoprotein (HDL) (Schaefer et al., 
2009). The mechanisms of circulating free fatty acids (FFA) for insulin-mediated effects on 
microvascular function are not completely understood. The elevated FFA  induces an increase in 
reactive oxygen species production (Lu et al., 1998). This leads to cause vascular endothelial 
dysfunction indirectly via increased release of the vasoconstrictor substance (Piatti  et al., 1996).  
Type 2 diabetes is one of the free radical diseases increases diabetic complications with 
increased lipid peroxides (Kumawat et al., 2012). Increased oxygen free radicals result in the 
lipid peroxidation of cellular lipids leads to macrovascular and microvascular complications in 
T2DM (Barathmanikanth et al., 2010). The main features of type 2 diabetic patients have plasma 
lipid alterations of Hypertriglyceridemia with decreased HDL (Miller et al., 2011). The presence 
of High plasma triglycerides and low plasma HDL cholesterol levels are an indicator of 
prediabetic state for individuals who had insulin resistance syndrome ( Fabbrini et al., 2010 and 
Mitsuyoshi et al., 2009). 
Hypercholesterolemia is higher in T2DM and it is also a common risk factor for the complication 
of progressive DN, DR , contributes to high cardiovascular morbidity and mortality of chronic 
kidney disease (CKD) patients and diabetic hypertension (Bakris,  2011 and Moorehead et al.,  
2005 ). Hypercholesterolemia characterized by high TG > 150 mg/dL and HDL > 40 mg/dL in 
men and cholesterol levels > 50 mg/dL and  a predominance of small dense low-density 
lipoprotein (LDL) >100 mg/dL ( Bakris,  2011 and Moorehead et al.,  2005 ). 
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3.4.2  Genetic Risk Factors 
Many of the studies have described that, genetic components play an important role in the 
pathogenesis of T2DM ( Harrison et al., 2013 and Amini & Janghorbani, 2007). Some of the  
studies reported that individuals who have a family history have an increased risk of  developing 
T2DM and the risk increases when both parents are affected ( Amini & Janghorbani, 2007 and 
Bjornholt et al., 2000). Specially,  monozygotic or twin individuals are highly affected with 
T2DM compared to dizygotic individuals (Medici et al., 1999). 
The prevalence of diabetes varies among different ethnic groups and this variation  across the 
different ethnic groups share a similar environment, which supports the idea of  genetic factors 
contribute to the predisposing of  disease (Elbein, 2006). Genetic factors predispose to the 
development of T2DM by reducing insulin sensitivity and insulin secretion (Gerich, 2007 and 
Elbein, 2006). The study by Lyssenko et al (2007) identifying 11 genetic variants (TCF7L2, 
PPARG, FTO, KCNJ11, NOTCH2, WFS1, CDKAL1, IGF2BP2, SLC30A8, JAZF1, and 
HHEX) and all are  associated with the risk of T2DM due to impaired beta-cell function but 
those genes are not associated with clinical risk factors ( Lyssenko et al., 2007). However, 
among the 11 genes, ACE gene was not included in the study. And the gene transcription factors 
7-like 2 (TCF7L2) is the highest risk of type 2 diabetes which results impairment of insulin 
secretion (Lyssenko et al., 2007).  
These days there are many genes associated for the occurrence T2DM and progress of diabetic 
complications. such as genes in the Renin-Angiotensin aldosterone system (RAAS), Endothelial 
nitric oxide synthesis (ENOS)  (Neugebauer & Baba, 2000), Glucose metabolism (Ricci et al., 
2006),  Cytoskeleton genes (Barry et al., 2009), Inflammation (Ahluwalia et al., 2009) , Growth 
factors, Oxidative stress (Yamagishi & Matsui, 2010), and lipid metabolism (Wu, 2014). 
However, this study focuses ACE gene polymorphism in RAAS, because this gene and other 
genes in the  RAAS such as angiotensinogen and  angiotensin II type 1 receptor gene plays a 
vital role in regulating glucose metabolism and blood pressure, electrolyte and fluid homeostasis 
those leads to pathogenesis of DM and  facilitate the progress of diabetic complications (Zhou 
and Schulman, 2009).  
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3.4.2.1  Gene polymorphisms in the Renin-Angiotensin-Aldosterone System 
Genes involved in this system are the major concern of this paper because genes of the Renin-
Angiotensin-Aldosterone System (RAAS) have many important roles than the above genes which is 
reported by many of the researcher, some of its role includes in glucose metabolism, and the 
regulation of blood pressure (Al-rubeaan et al., 2014), electrolytes and fluid homeostasisd 
(Ohshigel.,et al. 2010). The RAAS genes consist of renin (Liu et al., 2013), angiotensinogen 
(AGT) (Fogarty et al., 1996), angiotensin-1 converting enzyme (ACE) (Haque1 et al., 2010); 
Angiotensin converting enzyme 2 (ACE2), Angiotensin II type 1 receptor (AT1R) (Wysocki et al., 
2006) and Angiotensin II type 2 receptor (AT2R) (Bindom et al., 2010) all of these genes or 
genetic loci responsible for excess Ang II production or availability are potential candidates for 
development of diabetic complications. Because Angiotensin II (Ang II) is a powerful 
vasoconstrictor and increase in intraglomerular pressure results in proteinuria and 
glomerulosclerosis (Ha et al., 2015). Among those genes, this study will be focus on Angiotensin 
converting enzyme (ACE) gene insertion/deletion polymorphism because most of the studies 
were reported of this gene was highly associated with T2DM, diabetic with hypertension,  
diabetic retinopathy and diabetic nephropathy.  
3.4.2.1.1  Angiotensin Converting Enzyme 
In the 1950s Skeggs and colleagues, discovered an enzyme that converts ANG I to ANG II 
(named as hypertension I and hypertension II) (Leonard et al., 1956). Called “converting 
enzyme“. After a number of years later recognized an enzyme in human blood, called kininase II, 
which was able to degrade bradykinin (Kuoppala et al., 2000). Converting enzyme and kininase 
II is later shown to be the same enzyme ( Dorer et al., 1974) and today the enzyme is referred to 
as Angiotensin-converting enzyme. 
ACE gene is located at chromosome 17q23 and spans approximately 21kb DNA, consists of 26 
exons and 25 introns (Erdos, 1990). The amino acid domain of the ACE coded by exon 1 to exon 
12, while the carboxyl domain coded by exon 13 to exon 26. The gene encodes 2 isoforms of 
ACE. The somatic form (sACE) a glycoprotein composed of a single large polypeptide chain 
expressed in somatic tissue of vascular endothelial cells at the brush border of renal proximal 
convoluted tubule, epididymal duct epithelia and the jejunal villus (Sibony et al., 1993). The 
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other is testicular form (testis ACE, germinal ACE), expressed uniquely in germinal cells with a 
precise stage-specific pattern, starting in round spermatids and finishing in spermatozoa (Sibony 
et al., 1993).  
Angiotensin is produced by the action of renin on angiotensinogen to form inactive decapeptide 
Angiotensin I and its subsequent conversion to the biologically active octapeptide (Angiotensin 
II) by Angiotensin -converting enzyme which is mediated via the Angiotensin type 1 receptor 
(Carey & Siragy, 2003). Angiotensin converting enzyme (ACE) is a zinc metallopeptidase 
membrane-bound enzyme widely distributed in several types of cells including vascular 
endothelial cells, various absorptive epithelial cells, neurons, macrophages, T-lymphocyte and 
other mononuclear cells, male germinal cells, and is also present in a circulating form in 
biological fluids such as plasma, amniotic fluid, seminal fluids (Joyce-tan  et al., 2016 and Erdos, 
1990).  
In plasma and on the surface of endothelial cells, it converts the inactive decapeptide Angiotensin 
I into the vasopressor- and aldosterone-stimulating octapeptide Angiotensin II (Leonard et al., 
1956). It also inactivates bradykinin (BK) (Kuoppala et al., 2000),  a vasodilator nonapeptide 
involved in the control of vascular tone and implicated in inflammatory responses and finally the 
enzyme is involved in the metabolism of several other biologically active peptides because of its 
broad enzyme specificity and wide distribution in the body (Erdos, 1990). 
Angiotensin I converting enzyme (ACE) gene is one of the most enormously studied genes and 
the main part of this paper. Because it has the key role in the rennin-Angiotensin system (RAS) 
and its physiological application in different parts of the body (Moynahan et al., 2001). The 
polymorphism of this gene was first explained by Rigat and his coworkers, typically refers as the 
insertion (I) or deletion (D) of an Alu repetitive sequence of 287-bp  in intron 16 of the gene , 
found in three forms: D/D and I/I homozygote and I/D heterozygote (Rigat et al., 1990). Alu 
ACE I/D polymorphisms are also suitable markers for studying genetic variation in human 
populations (Skipworth et al., 2011and Yoshida et al., 1996). 
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3.4.2.1.2 Gender and ACE gene polymorphism 
Glucose utilization is higher in women with the DD genotype than in women with the II 
genotype, homozygous D allele women of the ACE gene are more insulin sensitive, whereas 
homozygous I allele women of the ACE gene have greater insulin resistance and potential risk 
for T2DM (Kaleemullah et al., 2011). A higher insulin level is an indirect indicator for insulin 
résistance, subjects with I allele are more insulin-resistance than non I allele individuals (Chiu & 
McCarthy, 1997). Study in south Indian population revealed that, the DD genotype is associated 
with the female population where as individual with  I allele (homozygous II and heterozygous 
ID) in unaffected males which act as a  protective role in male population (Nagamani et al.,  
2015). However, the other study conducted in China indicated that male subjects with DD 
genotype had higher serum ACE activity than female subjects with DD genotype (Zhang et al., 
2014) 
3.4.2.1.3 Metabolic syndrome and ACE gene polymorphism 
Metabolic syndrome is a collective effect of genetics and certain environmental factors which 
results glucose intolerance, hypertension, abdominal obesity and dyslipidemia (Reaven,1988)  
Study in china related to association of the ACE I/D polymorphism with metabolic syndrome in 
patients with T2DM have a higher prevalence of dyslipidemia, albuminuria, serum uric acid and 
serum triglyceride levels it provides genetic information of  the renin-Angiotensin system 
involved in the pathophysiology of metabolic derangement (Lee & Tsai, 2002).  
Study in USA about glucose metabolism notify that, fasting glucose and insulin are  similar 
among genotypes of ACE gene, but 2-hour  glucose levels were higher in DD genotype which 
has lower insulin sensitivity than in ID and II genotype subjects (Bonnet et al., 2008). The other 
study by Ali-Bahara et al., (2014) reported that a decrease in DD genotype of ACE and increases 
in ID and II genotypes are associated with changes in fasting blood sugar, triglyceride, total 
cholesterol and blood pressure (Ali-Bahar et al., 2014). However, the other study conducted in 
Iranians T2DM patients indicated that metabolic syndrome is not associated with ACE gene 
polymorphism (Nikzamir et al., 2008). 
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3.4.2.1.4 ACE Insertion/Deletion and Susceptibility to Diabetes Mellitus 
There are may candidate genes associated to the ourrence of T2DM such as glucokinase (GCK), 
insulin receptor substrate-1 (IRS-1), potassium inwardly rectifying channel subfamily J member 
11 (KCNJ11), peroxisome proliferator-activated receptor gamma, hepatocyte nuclear factor- 1A 
(HNF1A) and hepatocyte nuclear factor-4A (HNF4A) (Singh, 2011). However, genetic variants 
in the RAAS are highly associated with metabolic syndrome, especially hypertension, T2DM and 
diabetic complications (Al-Rubeaan et al., 2013). Activation of the RAAS and enhanced 
production of Ang II has an inhibitory effect on insulin signal transduction pathway of insulin 
IRS-1 phosphorylation and reduce glucose uptake through GLUT4 that result for insulin 
resistance (Zhou and Schulman, 2009).  Additionally, Ang II increases reactive oxygen species 
which leads to damaging the pancreatic β-cells and causes impair insulin secretion from the 
pancreas through vasoconstriction and reduction in islet blood flow. All these effects lead to the 
development of DM (Zhou and Schulman, 2009) and activation of RAAS leads to the 
development of hypertension, macrovascular and microvascular complication in patients with 
diabetes mellitus (Hsueh and Wyne, 2011). 
The role of ACE I/D polymorphism in the pathogenesis of diabetes mellitus and its complications 
were reported in various populations. Angiotensin II (AngII) has been confirmed in the 
pathogenesis of T2DM by inhibiting the secretion of insulin or producing of insulin resistance, 
promoting the generation of inflammation and fibrosis (Yusuf et al., 2001 and Danser et al., 
1995). The DD genotype of the ACE gene is mostly associated in the pathogenesis of T2DM and 
individuals having DD genotype are highly susceptibility to T2DM (Yang et al., 2006 and Ergen 
et al., 2004 ). The study in Egypt also indicated ACE gene I/D polymorphism are associated with 
T2DM patients and the D allele is high risk for T2DM (Zarouk et al., 2009).   However, a meta-
analysis study indicated that there was no association between ACE gene polymorphism and 
T2DM in Chinese population (Zhou et al., 2012). Similarly, other studies reported that ACE gene 
polymorphism (I/D) cannot be considered as a risk factor for T2DM in the Lebanese population 
(Chmaisse et al., 2009), in Japan (Ichikawa et al., 2014).  Moreover, the relationship between 
ACE gene polymorphism in T2DM, diabetic complications and diabetic hypertension in the 
diabetic population has not any reported data in the Ethiopian population.  
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3.4.2.1.5   ACE gene Polymorphism in Patients with Diabetic Nephropathy 
ACE is a component of the renin–Angiotensin system and catalyses the conversion of the 
inactive precursor decapeptide Angiotensin I to active octapeptide Angiotensin II. Angiotensin II 
leads to the release of catecholamines from the adrenal medulla and prejunctional nerve, induces 
vasoconstriction, sodium retention and renal hemodynamic changes that result in intraglomerular 
hypertension and causes glomerulosclerosis (Hsueh and Wyne., 2011 and Leehey et al., 2000). 
In T2DM, patients there are conflict regarding the association between the ACE genotype and 
diabetic nephropathy (Schmidt et al., 1995 and Fujisawa et al., 1995). The homozygous DD 
genotype is an independent risk factor and has a high prognostic value for the onset and 
progression of diabetic nephropathy in T2DM. The study in India showed that haplotypes, 
deletion allele D and DD genotype of the ACE gene are associated with greater risk of diabetic 
nephropathy than the haplotypes insertion(I) allele ( Haque et al., 2010 and Naresh et al., 2009). 
However study in Turkish (Mustafa et al., 2001), Switzerland (Walder et al., 1998), and 
Germany (Schmidt et al., 1995) were revealed that, type 2 diabetic patients of ACE I/D 
polymorphism genome distribution and allele frequencies (DD, ID, II and D and I ) doesn’t seem 
to be associated with diabetic nephropathy.  
Studies in Iran shows that, the frequency of DD genotypes  and D alleles are increased in DN 
patients than the normal individuals (30.6% vs 14.3%) (Nikzamir et al., 2006). The other follow-
up study in Iraq reported that, the genotype and allele frequencies of ACE gene polymorphism of  
the homozygous DD genotype are at high risk of DN which is two folds than wild type II and the 
minor allele frequency D allele is higher in DN than the normal individuals (Hussein et al., 
2015).  In addition to this during their follow-up studies, they also concluded that, the frequency 
of DD genotype was not differing between DN patients and patients without nephropathy (30.6% 
vs. 20%) (Hussein et al., 2015). In contrast, the l/D polymorphism (DD, ID and II) of ACE  
genotype has not  associated in patients with and without nephropathy with the duration of  
diabetes ≥20 years Arfa et al., 2008 and (Schmidt et al., 1995). Also the other study in Japanese 
reveal that the ACE gene polymorphism is associated with myocardial infarction, but not with 
nephropathy patients of NIDDM (Fujisawa et al., 1995). 
The ACE DD genotype polymorphism is associated with more rapid decline GFR which 
increases mortality rate in type 2 diabetic patients with established renal disease, and the D allele 
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has also  a co- dominant effect on the development of diabetic nephropathy but not associated 
with non-diabetic nephropathy ( Zarouk et al., 2009 and Fava et al., 2001 ).  
3.4.2.1.6  ACE Gene Polymorphism in Patients with Diabetic Hypertensive 
The product of ACE (Angiotensin II) induces vasoconstriction through inactivation of the 
vasodilator peptide bradykinin, theses leads to the occurrence hypertension (Hsueh and Wyne, 
2011 and Leehey et al., 2000). The association between ACE I/D polymorphism and 
hypertension is controversial. Some of the studies have proposed that the DD genotypes are 
increase numbers of critical hypertension in the diabetic population (Pasquale et al., 2005 and 
O’Donnell et al., 1998) and D allele with hypertension in a south Indian population (Anbazhagan 
et al., 2009) and in a south China population (Jiang et al., 2009).  Others have not established as 
a significant relationship between ACE DD genotype and D allele among hypertensive 
individuals (Tascilar et al., 2009 and Chuang et al., 1997). The study in Iranian patients with the 
frequency of DD genotype (27 cases in T2DM with hypertension Vs 11 cases in T2DM without 
hypertension P < 0.026) indicates that DD genotype individuals are independently associated 
with hypertension in the diabetic population (Nakhjavani  et al., 2007). 
ACE gene DD genotype and D allele is a risk factor for hypertension and higher lipid levels but 
is not a risk factor for diabetes in elderly population than those in patients with II genotype 
without association of their blood glucose level (Zhou et al., 2013). However, the other study 
indicate that I allele 63% and I/D genotype 37% in patients and 48% I allele and 52% I/D 
genotype for healthy controls of ACE gene which indicates I allele and I/D genotype is 
associated with T2DM and hypertension (Panjaliya et al., 2013 ).  
3.4.2.1.7  ACE Gene Polymorphism in Patients with Diabetic Retinopathy 
Genetic factors are contributed in the developmental role of diabetic retinopathy (Abhary et al., 
2009). A number of gene polymorphism studies on the components of retinal RAS such as Ang I, 
Ang II, renin, ACE, AT-1 and AT-2 leads to increase levels of prorenin, rennin and angiotensin II 
are associated with proliferative DR and diabetic macular edema telling the connection of RAS 
in pathogenesis of diabetic retinopathy (Lu et al., 2012; Noma, 2009; and Nagai N, 2005). 
However, the biological mechanism through which the ACE I/D polymorphism related to an increased 
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risk of proliferative diabetic retinopathy is unclear. It is reported that Ang II participates in the progress of 
retinopathy through inducing the synthesis of growth factors in the vascular endothelial and connective 
tissue (Wilkinson-Berka, 2006).  
 A meta-analysis study includes 2,224 Chinese patients showed reasonable evidence of an association 
between the ACE I/D polymorphism and proliferative diabetic retinopathy (PDR) (Lu et al., 2012). The 
study in Pakistan also shows that the ACE genotype I/D is associated with PDR (p = 0.009) and 
its sub-clinical class non-proliferative diabetic retinopathy (NPDR) (p = 0.006) (Saleem et al., 
2015). The other study in Turkey revealed that ACE DD genotype is an independent risk factor 
for retinal vein occlusion (second most common retinal vascular disease after diabetic 
retinopathy in the elderly and it leads to serious visual loss and blindness) (Kutluturk et al., 
2014). 
Numerous studies have addressed the molecular epidemiology of ACE I/D polymorphism among 
DR (Thomas et al., 2003 and Marre et al., 1994). A recent study in china indicated that ACE 
gene polymorphism have no difference between DR males and females compared to respective 
controls other than used for a risk factor and prognostic marker for DR and T2DM (Khan et al., 
2015). Treatment with blockage of the RAS provides beneficial effects in the provisions of 
delaying the development and progression of diabetes and DR (Sjolie et al., 2008).   
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4. MATERIAL AND METHODS 
4.1 Study Area 
 
This study was conducted in Bahir Dar Felegehiwot Referral Hospital. Bahir Dar town is located 
in the Amhara region, Northwest of Ethiopia served by Felegehiwot Referral Hospital, a tertiary 
referral hospital serving over 7 million people from the surrounding area including Debretabor 
hospital, Woreta hospital, Dangla hospital, Durbetie hospital, Merayi hospital,  Adiet hospital, 
Enjibara hospital, Gemjabet hospital, Burie hospital, Chagni hospital, Pawi hospital and Mota 
hospital. For this study, samples were collected from the diabetic clinic of Bahir Dar Felegehiwot 
Referral Hospital. The biochemical analysis of the study was done in Gondar University Referral 
Hospital, clinical diagnostic laboratory. However, the molecular part of the experimental analysis 
was conducted in Gondar University Atse Tewodros Campus, College of Natural and 
Computational Sciences, Department of Biotechnology. 
4.2 Study Design and Period 
 
A case control comparative study was carried out from January – October, 2016 in Bahir Dar 
Felegehiwot Referral Hospital.  
4.3 Population 
 
During the study period, all patients who were diagnosed by physicians according to the WHO 
criteria for diabetes mellitus and healthy control subjects were the source population. Whereas 
T2DM without complication, type 2 diabetic hypertension, diabetic retinopathy and diabetic 
nephropathy patients who were diagnosed by physicians were the study population. 
4.4 Inclusion and Exclusion Criteria 
 
Patients diagnosed by physicians having type 2 diabetes, diabetic hypertension, diabetic 
retinopathies, diabetic nephropathies and all age groups were recruited in the study. Patients 
were diagnosed with T1DM, patients suffering from acute and chronic infection, malignancies, 
congestive heart failure, HIV, urinary tract infection and acute febrile illness were excluded from 
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this study.  Healthy controls having hypertension at the time of data collection and healthy 
controls having hyperglycemia during biochemical analysis were excluded in the study and 
replaced by other healthy individuals.  
4.5 Variables 
 
The dependent variables in these studies were age, sex, duration of diabetics and status of 
diabetes. Whereas the independent variables include serum creatinine, glucose level, cholesterol, 
triglycerol, blood urea,  ACE gene I/D polymorphism, and obesity. 
4.6 Sample Size and Sampling Technique 
 
A total of 222 subjects (111 T2DM and 111 healthy controls) were selected by non probability 
purposive sampling technique. Among 111 T2DM, 35 had T2DM without complications, 35 had 
diabetic hypertension, 30 had diabetic retinopathy and 11 had diabetic nephropathy. Among 
T2DM, 55 were men and 56 were women and healthy control groups consisted, 55 men and 56 
women. 
4.7  Data Collection, Clinical Measurements and Laboratory Method 
4.7.1  Questionnaire 
The socio- demographic characteristics and clinical parameters of both patients and  healthy 
control subjects such as smoking, gender, age, duration of diabetes, diabetic complications and 
family history were taken through semi-structured questioner.  
4.7.2 Anthropometric Measurements 
Body weight was measured using a portable digital scale while height was measured using a 
portable stadiometer. Body mass index (BMI) was calculated as weight in kilograms divided by 
the square of height in meters and participants were categorized as underweight < 18.5, healthy 
(BMI 18.5 - 25 kg/m2), overweight (BMI 25.0–29.9 kg/m2) or obese (BMI ≥ 30 kg/m2) 
(Ferguson et al., 2011). Blood pressure was recorded in the sitting position after 5 min of rest by 
using a digital device and systolic and diastolic blood pressures were calculated from mean value 
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after three readings. Patients were considered as hypertension, if mean systolic blood pressure 
(SBP) ≥ 140mmHg and mean diastolic blood pressure (DBP) ≥90mmHg Or if they used 
antihypertensive medication. 
4.7.3  Sample Collection 
Five milliliters of blood sample were collected from the vein of all subjects of an overnight 
fasting patients and healthy controls by laboratory personnel. From 5ml blood sample, 3ml was 
kept in plain tube without anticoagulants for biochemical tests. The remaining 2ml of the blood 
was kept in Ethylene Diamine Tetra Acetic Acid (EDTA) tube for isolation of DNA and stored at 
-21ºC. 
4.7.4  Laboratory Methods 
4.7.4.1  Biochemical Analysis 
A non –anticoagulated blood (3ml in plain tube) sample was centrifuged at 8000 rpm for 10 
minutes, the sera were aspirated and transferred in to sterilized eppendorf tube and stored at –20 
0C until processing. Each test was subjected for an enzymatic analysis of Glucose, total 
cholesterol, triglycerides, urea, and creatinine by Mindary fully automated analyzer in the 
clinical chemistry diagnostic laboratory of college of medicine and health sciences. Fasting 
blood glucose (FBG) level was used to assess the glycemic control. For a non diabetic 
individuals (healthy control group), when FBG was > 110 mg/dl, the glycemic control was 
considered as unsatisfactory; when FBG ≤ 110 mg/dl the glycemic control was considered as 
satisfactory (American College of Endocrinology, 2002). However, in the case of diabetic 
patients when FBG >130mg/dl, the glycemic control was considered poor glycemic control.  
When FBG <130mg/dl, the glycemic control was considered good glycemic control (Kassahun 
et al., 2016). If total cholesterol > 200 mg/dl and triglycerides > 150 mg/dl, were taken as 
abnormal (NCEP 2001). If serum creatinine > 1 mg/dl, it was taken as abnormal result (Colagiuri 
et al., 2015). Estimated glomerular filtration rate (eGFR) was calculated online by using the 
Chronic Kidney Disease Epidemiology Program equation (CKD-EPI) and individuals having 
eGFR < 60 ml/min/1.73m2 were considered as having a chronic kidney disease (Levey et al., 
2009). Moreover, based on eGFR, individuals were classified as risk categories (low, moderate, 
 high or very high) by the Kidney Disease Improving Global Outcomes (KDIGO) 2012 
prognostic grids (KIDGO, 2013).
4.7.4.2
For DNA extraction, 300µl of EDTA anticoagulated blood
was transferred in to sterilized 1.5ml eppendorf 
used for DNA extraction to get 
(Suguna, et al., 2014). Red blood cells (RBCs) were lysised and removed by using RBC lysis 
buffer solution. Similarly, white blood cells were lysised using a nuclear lysis buffer solution. 
The proteins were precipitated with a high concentrated salt (6M NaCl) and DNA was 
precipitated by chilled absolute ethanol, followed by washing of genomic DNA with 70% ice
cold ethanol and finally the DNA was dissolved with 
was stored at -210c till used. 
The quality of isolated genomic DNA was confirmed by using 1.5 % aga
Finally via following the above mentioned
shown in the Figure 1. Then the patients and respective control samples were genotyped for 
Insertion/Deletion (I/D) polymorphism using sets of primers and appropriate PCR conditions. 
 
 
 
  Genomic DNA Isolation 
s of both patients and 
tube. A non-enzymatic salting out method was 
high yield genomic DNA with a small amount of blood sample 
Tris-EDTA buffer (TE) and
rose gel electrophoresis. 
 procedures a pure genomic DNA was obtained as 
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healthy controls 
-
 this sample 
ACE 
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4.7.4.3 Polymerase Chain Reaction (PCR) 
The Insertion/Deletion (I/D) alleles of ACE gene polymorphisms were identified by TC 412 PCR 
amplification of using specific primers. A final volume (25 µl) of  PCR reaction mixture were 
prepared using 6pmol of forward and reverse primers (forward primer 5′- 
CTGGAGACCACTCCCATCCTTTCT-3′ and reverse primer 
5′GATGTGGCCATCACATTCGTCAGAT-3′) (Patel et al. 2011 and Rigat et al.1992), 5 mM of 
MgCl2, 0.5 mM of each dNTP, 0.75 U of hot start Taq polymerase, 3 µl of template DNA and 
water were used. 
PCR amplification was set with an initial denaturation at 95°C for two minutes. Hot start Taq 
polymerase was kept for 15 minutes at 95°C to activate the enzyme. Then, the DNA was 
amplified for 30 cycles. The cycle steps were denaturation at 94°C for 30 seconds, annealing at 
62°C for 30 seconds and extension at 72°C for 45 seconds followed by a final extension at 72°C 
for nine minutes. Finally the PCR product was held at 40c until it was analyzed by agarose gel 
electrophoresis. 
4.7.4.4  Agarose Gel Electrophoresis 
PCR amplified products of ACE I/D genotypes were electrophoretically separated for 50min at 
50 V on a 2% agarose gel. To stain and visualize DNA upon UV transillumination in gel, 3 µl of 
2% Ethidium Bromide was also added. The PCR amplified products (12µl) mixed with 3 µl 
loading dye then loaded into wells of agarose gel. Electrophoresis was carried out in 1X trice 
acetate EDTA (TAE) buffer and the gel was visualized by UV transilluminator. 
 After electrophoresis, band sizes of 190bp (Deletion) and 490bp (Insertion) polymorphisms 
fragments were obtained and image was captured with the help of a smart phone camera and 
digital camera. Therefore, there were three genotypes after electrophoresis: A 490bp band 
(genotype II), a 190bp band (genotype DD) and both 490bp and 190bp band (ID genotype). The 
genotypes were calculated to determine the association of ACE (I/D) gene polymorphisms in 
patients with T2DM, DR, DN, diabetic with hypertension and with other clinical and socio-
demographic characteristics. 
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4.8  Statistical Analysis  
 
Data were analyzed by using SPSS version 20. Quantitative data were presented as mean and 
standard deviation (x ± s). To compare continuous variables between T2DM group and healthy 
control groups, T2DM and T2DM complication, t-test for independent samples was used. 
Distribution of the genotype and allele frequencies in T2DM and healthy control groups, T2DM 
and T2DM with complications were compared using chi-square test. The risk associations of DD 
genotype and D allele with T2DM were assessed by the odd ratio at 95% confidence interval 
(CI). Relationships between the ACE genotypes and clinical variables were compared with one-
way analysis of variance (ANOVA).  
4.9  Ethical Consideration 
 
The study protocol was approved by the college of natural and computational sciences ethical 
committee of the University of Gondar on its meeting held on 11/08/08 ethical clearance. To take 
care and keep confidentiality of participants result, written informed consent was obtained from 
all study participants before collecting of blood sample. 
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5. RESULTS 
5.1  Demographic, Clinical and Biochemical Characteristics between T2DM and 
Healthy Controls. 
The demographic parameter of study subjects is given in Table 1. There was no statistically 
significant variation between cases and controls in respect to age and sex. Among cases, 55 were 
men and 56 were women, (P 0.789), their mean age was 54.6±12.2 years. The control group 
consisted, 55 men and 56 women their mean age was 54.0±14.4 years, (P 0.811). The clinical 
characteristics systolic blood pressure (SBP), diastolic blood pressure (DBP), glucose, total 
cholesterol, triglycerol and urea have shown a significant difference (P < 0.001), BMI (P < 0.05) 
and creatinine (P < 0.02) higher in T2DM than control group.  However, eGFR was not 
significantly differed between the two groups (P 0.052).    
Table 1: Demographic, Clinical and biochemical characteristics of T2DM patients and healthy 
controls 
Variables T2DM Control P value 
Subject (n) 111 111 ------ 
Gender (M/F) 55/56 55/56 0.789 
Age (yr) 54.7±12.3 54.3±14.4 0.811 
BMI(kg/m2) 24.9±4.4 23.6±5.4 0.049 
SBP(mmHg) 133.7±19.5 121.2±6.9 0.000 
DBP(mmHg) 82.6±13.6 76.4±5.5 0.000 
Glucose(mg/dl) 206.3 ±72.3 78.2 ±15.6 0.000 
TC(mg/dl) 194.81±47.6 130.4 ±48.9 0.000 
TG(mg/dl) 177.5 ±135.3 99.6 ±56.7 0.000 
Creatinine(mg/dl) 0.7 ±0.2 0.6 ±0.1 0.010 
Urea(mg/dl) 22.2 ±8.3 18.8± 4.6 0.000 
eGFR 118.4 ±27.1 124.7 ±20.2 0.052 
 
Data expressed as means ± SDP<0.05 were considered as significant and P> 0.05 (not significant) Note: BMI: Body mass index. 
SBP: Systolic blood pressure. DBP: Diastolic blood Pressure. TC: Total cholesterol, TG: Triglycerol, eGFR: Estimated 
glomerular filtration rate. 
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5.2  Demographic, Clinical and Biochemical Characteristics between T2DM, Diabetic 
Complications and Diabetic Hypertension.  
 
Gender, total cholesterol and triglycerol had not any significant association among the groups 
(Table 2). However, age (P < 0.02); DBP (P < 0.001) and urea (P < 0.05) have shown a 
significant association in hypertensive diabetic population compared with T2DM and other 
complications. SBP was significant for both diabetic hypertension (P < 0.001) and diabetic 
nephropathy (P < 0.05) patients. Creatinine (P < 0.01) and eGFR (P < 0.01) had shown 
statistically significant association only in diabetic nephropathy patients. Glucose (P < 0.02) was 
significant only in diabetic retinopathy patients.  
Table 2: Comparison of demographic, clinical and biochemical variables between T2DM and its 
complications. 
 
Variable                             Group 1                                  Group 2                      Group 3                         Group 4        
Gender  (M/F) 20/16                                   19/15 
                      P   0.896 
11/19 
P  0.128 
5/ 6 
P  0.569 
Age(yr) 50.6± 13.3                        57.6±10.4 
P*    0 .018 
55.9 ± 11.5 
P   0.089 
55.3 ± 16.0 
P   0.397 
BMI(kg/m2) 24.7± 3.7                        25.1 ± 5.8 
P   0.662 
24.7 ± 3.9 
P  0.990 
24.8 ± 5.2 
P   0.962 
SBP(mmHg) 121.8±10.2                       153.3 ± 16.3 
P* 0.000 
126.3 ± 16.8 
P 0.209 
130.5 ± 17.1 
P٭  0.047 
DBP (mmHg) 75.6±7                            96.4 ± 9.6 
P٭ .000 
73.5 ± 9.7 
P   0.333 
79.1 ± 12.2 
P   0.383 
Glucose(mg/dl) 192.9 ± 65.2                     194.0 ± 75.8 
P  0.952 
239.9 ± 82.3 
P٭ 0.014 
194.2 ± 59.8 
P  0.955 
Cholesterol(mg/dl) 190 ± 50.7                      205.3 ± 50.2 
P   0.210 
186.9 ± 50.8 
P   0.801 
198.6 ± 51.4 
P  0.638 
Triglycerol(mg/dl) 156.6 ± 65.4                     191.6± 182.1 
P  0.291 
165.7± 107.7 
P 0.689 
169.0± 148.9 
P  0.793 
Creatinine(mg/dl) 0.7 ± 0.2                           0.77 ± 0.3 
P  0.235 
0.64 ± 0.24 
P 0.225 
0.9 ± 0.3 
P٭  0.009 
Urea(mg/dl) 22 ± 7.5                          26.4  ±  8.4 
P٭0.028 
18.0 ± 8.2 
P  0.044 
23.3± 6.97 
P   0.612 
eGFR 122.6 ± 19.7                      112.7 ± 28.3 
P  0.096 
124.3 ± 29.3 
P  0.765 
99.6 ± 27.8 
P٭  0.004 
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 Data expressed as means ± SD, P<0.05 were considered as significant and P> 0.05 (not significant). Note: Group 1 , type 2 
diabetes; group 2, type 2 diabetes with hypertension; group 3, type 2 diabetes with retinopathy and group 4, type 2 diabetes with 
nephropathy. Group 1, was compared with group 2, 3 and 4.
 
5.3 ACE Genotype distribution in T2DM Patients and Healthy Controls 
 
The ACE genotypes frequency distribution in patients with type 2 diabetes and healthy control is 
given in table 3. The ACE DD genotype and D allele were more frequent in diabetic patients 
(64.2% and 79.3 %) as compared to controls (35.6% and 59.9%). The frequency of homozygous 
DD genotype in type 2 diabetic patients was twofold higher than healthy control group (OR, 
2.984: CI 1.332 – 6.689). D allele was five times than I allele in diabetic patients (OR, D 2.178; 
CI: 1.168 – 3.232 P < 0.001) compared to healthy controls (I OR, 0.459; CI: 0.309 – 0.681 P < 
0.001). However, ACE genotype I/D and II were less frequent in T2DM patients (31.4% and 
37.5%) in comparison to healthy controls (69.0% and 62.5 %). 
Table 3: Distribution of ACE genotypes and allele frequencies between T2DM and Healthy 
Control participants. 
 
P < 0.001 (statistically significant) 
 
Genotype T2DM Control OR OR 95% CI P  
DD 77 (64.2%) 42 (35.6%) 2.984 1.332 -
 6.68
9 
0.008  
ID 22 (31.4%) 49 (69.0%) 0.7641 0.318 - 
0.834 
0.547  
II 12 (37.5%) 20 (62.5 %)     
P-value  .000            X2      21.290a     
Allele frequencies 
D 176 (79.3 %) 133(59.9%) 2.178 1.468 - 3.232 0.000  
I 46 (20.7 %) 89 (40%) 0.459 0.309 - 0.681 0.000  
P-value  0.000            X2      22.562a  
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5.4  Association of ACE I/D Genotype with Clinical and Biochemical Characteristics of 
T2DM and Healthy Controls. 
 
The ACE DD genotype was highly associated with the clinical variables than I/D and II 
genotypes. SBP (131.5±18.9 VS 123.2±8.3 and 121.3±10.7), glucose (168.2±86.8 Vs 110.5±61.9 
and 114.7±75.6), total cholesterol (179.2±56.8 Vs 141.2±57.1 and 145.0±42.7), triglycerol 
(167.5±136.3 Vs 102.4±51.8 and 109.3±53.9) and urea (22.7±7.6 Vs 17.9±5.1 and 17.8±4.3) had 
P < 0.001, DBP (81.9±12.4 Vs 77.4±6.5 and 75.2±9.6) (P < 0.01) and BMI (24.9±4.4 Vs 
24.2±5.8 and 22.0±4.3) (P < 0.02) respectively (Table 4). 
Table 4: One-way ANOVA analysis of clinical and biochemical characteristics according to 
ACE genotype in T2DM and healthy controls. 
 
 
Data expressed as means ± SD, P<0.05 were considered as significant and P> 0.05 (not significant) Note: SBP, systolic blood 
pressure; DBP, diastolic blood pressure; Glu, glucose, TC, total cholesterol; TG, Triglycerol; CRT, creatinine; eGFR, estimated 
glomerular filtration rate; BMI, body mass index. 
 
Genotype 
result 
Age  SBP DBP Glu TC TG CRT Urea eGFR BMI 
DD 54.9±
12.8 
131.5±
18.9 
81.9±
12.4 
168.2±
86.8 
179.2±
56.8 
167.5±
136.3 
.697±.
24 
22.7±
7.6 
120.2±
27.8 
24.9±4
.4 
ID 54.6±
14.2 
123.2±
8.3 
77.4±
6.5 
110.5±
61.9 
141.2±
57.1 
102.4±
51.8 
.644±.
2 
17.9±
5.1 
122.9±
18.4 
24.2±5
.8 
II 52.3±
13.9 
121.3±
10.7 
75.2±
9.6 
114.7±
75.6 
145.0±
42.7 
109.3±
53.9 
.699±.
18 
17.8±
4.3 
123.6±
19.5 
22.0±4
.3 
p-value .610 .000 .001 .000 .000 .000 .257 .000 .663 .014 
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5.5 ACE Genotype Distribution in T2DM, Diabetic Complications and Diabetes   with 
Hypertension. 
 
As shown in Table 5, the frequency distribution of ACE genotypes and alleles among T2DM and 
its complications were indicated. The frequency of ACE DD genotype (41.6%, 28.6%, 19.5%, 
and 10.4%, P < 0.01) and D allele (60.4%, 44.1%, and 37.8% and 18.0%, P < 0.001) was more 
frequent in T2DM patients with hypertensive and diabetic retinopathy complication than T2DM 
without complication and diabetic nephropathy patients respectively.  
 Table 5:Frequency of ACE I/D genotype and allele polymorphism T2DM and diabetic complications. 
 
P< 0.05 (Statistically significant) 
 
Genotype  T2DM without 
complication 
    Diabetic 
hypertension 
    Diabetic   
Retinopathy 
Diabetic with Nephropathy 
DD 15 (19.5.0%)  32 (41.6%)    22 (28.6%)
  
                 8(10.4%) 
ID 12 (54.5%) 3 (13.6 %) 5 (22.7%)                  2(9.3%) 
II 7 (58.3%) 0(.0%) 3 (25.0%)                  1(8.3%) 
P-value       0.002                 X2- 20.713a   
  
D allele                               42 (37.8%) 67(60.4%)
  
49 (44.1%) 20 (18.0%) 
     
I allele 26 (23.4%) 3 (2.7%) 14 (12.6%) 4 (3.6 %) 
p-value    0.000       X2     34.892a    
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5.6 One way ANOVA of ACE Genotype Distribution to the Associated Risk Factors 
among T2DM and Diabetic Complications 
 
The companied one way ANOVA of clinical characteristics of T2DM and its complication with 
respect to ACE genotype indicated in Table 6. There had no any significance difference in 
glucose, diabetic duration, BMI, triglycerol, creatinine and eGFR among type 2 diabetes and its 
complications. Whereas age (56.6±11.2, P < 0.04), SBP (138.4±21.2, P < 0.01), DBP (84.2 ± 
14.0, P < 0.01), total cholesterol (203.7±45.3, P < 0.01), urea (24.5 ± 8.5, P < 0.001) were 
significance different among the groups.  
Table 6: Companied one- way ANOVA distributions of ACE I/D genotype and clinical 
characteristics among T2DM, DR, DN and diabetic with hypertension. 
 
Data expressed as means ± SD, P<0.05 were considered as significant and P> 0.05 (not significant) Note:  SBP, systolic blood 
pressure. DBP, diastolic blood pressure. eGFR estimated glomerular filtration rate. 
 
 
 
Genotyp
e result 
 
 
Age  
 
 
BP 
 
 
DBP 
 
 
Glucose 
Total 
cholestro
l 
Trigly
cerol 
 
Creatin
ine 
 
 
Urea 
 
 
eGF
R 
 
 
BMI 
Duratio
n of 
diabetes 
DD 56.6±
11.2 
138.4±
21.2 
84.2 
± 
14.0 
215.3±7
1.5 
203.7±45
.3 
186.1±
149.2 
0.74 ± 
0.26 
24.5 ± 
8.5 
115.2 
± 
27.1 
24.7
± 4.9 
8.1 ± 
4.7 
ID 52.9±
12.5 
125.0±
12.2 
79.1±
12.1 
178.2±6
0.5 
186.0 ± 
55.8 
144.9 ± 
51.8 
0.72± 
0.23 
17.8 ± 
6.8 
116.6 
± 
19.5 
25.3 
± 3.7  
8.5 ± 
4.3 
II 47.3±
17.0 
121.0 
±9.8 
72.3±
5.8 
193.9 
±108.1 
148.8 ± 
53.5 
123.4 
±63.2 
0.69 ± 
0.26 
16.9 ± 
6.4 
133.7
±32.3 
25.5 
± 4.3 
6.8 ± 
3.6 
p-value 0 .037 0.001 .008 0.105 0.001 0.171 0.842 0.000 0.081 0.777 0.596 
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Table 7: Shows ACE genotype distribution regarding to clinical variables with a comparison of 
T2DM to its complications. eGFR, creatinine, triglycerol, body mass index, and gender did not 
show statistically significance variation between T2DM and its complication respect to ACE 
genotype (P > 0.05).  Age has shown statistically significant association in patients having 
diabetic hypertension DD genotype (56.8 ± 11.0, P < 0.05). Similarly, systolic and diastolic 
blood pressure indicated statistically significant association in diabetic hypertension of DD 
genotype (P < 0.001 and P < 0.01) respectively. Urea was significant in all complication and had 
highest x±s was recorded among DD genotype (26.6 ± 8, P <0.01), (22.4 ± 8.6 P < 0.02), (25.6 ± 
7.3 P < 0.01) in diabetic with hypertension, retinopathy and nephropathy. There was no 
statistically significant association between glucose level and ACE I/D genotypes among diabetic 
hypertension individuals. However, DD genotype individuals among diabetic retinopathy (P < 
0.02) and nephropathy (P < 0.05) showed statistically significant variations to the level of 
glucose. Total cholesterol level indicated statistically significant association in diabetic 
retinopathy patients DD genotype (DD 200.6 ± 42.6, ID 184.3 ± 53.3, II 147.8 ± 56, P < 0.01). 
Table 7: One- way ANOVA ACE genotype distribution and clinical characteristics in 
comparison to T2DM to its complications. 
 
 
Variable      
T2DM Vs  Diabetic 
Hypertension 
T2DM Vs  Diabetic 
Retinopathy   
T2DM Vs Diabetic  
Nephropathy 
 Sex (F/M)    15/20 
  P   0.147 
 16/19 
P  0 .178 
     6/ 5 
P  0.064 
Age  DD (  56.8 ± 11.0) 
ID (  49.1 ± 11.7) 
II (  49.2 ± 17.3) 
P  0.049 
 
DD (55.2 ± 11.2)  
ID (51.9 ± 12.9) 
II (49.1 ± 16.6) 
 P   0.329  
DD (55.2 ± 12.2) 
ID (50.3 ± 13.7) 
II (47.1 ± 17.9) 
          P  0.277 
BMI DD (24.8 ± 5.2)  
ID (26.2 ± 4.2) 
II (24.6 ± 3.9) 
   P  0.593 
DD (24.5 ± 3.7 ) 
ID(24.7 ± 3.7) 
II (25.8 ± 4.4) 
  P  0.647 
DD (24.9 ± 4.4) 
ID (25.0 ± 3.9) 
II (24.4 ± 3.7) 
           P   0.940 
Systolic DD ( 144.4 ± 20.3) 
ID ( 126.3 ± 14.3) 
II ( 118.4 ± 10.2)  
  P* 0 .000 
DD (125.7 ± 16.4) 
ID(122.9 ± 8.5) 
II (119.7 ± 9.2) 
 P   0.428 
DD (125.9 ± 14.7) 
ID (123.2 ± 8.9) 
II (120.2 ± 11.0) 
   P    0 .508 
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Data expressed as means ± SD, P<0.05 were considered as significant and P> 0.05 (not significant) Note: T2DM, type 2 diabetes 
mellitus. BMI, body mass index. eGFR, estimated glomerular filtration rate.T2DM was compared with T2DM with hypertension, 
retinopathy and nephropathy. 
 
 
 
Diastolic DD ( 89.3 ± 13.2) 
ID ( 83.7 ± 11.3) 
II ( 70.9 ± 6.2 ) 
    P٭ 0.001 
DD (74.5 ± 9.2) 
ID (76.8 ± 7.5) 
II (71.6 ± 5.5) 
P  0.270 
DD (76.7 ± 9.4) 
ID (78.6 ± 7.4) 
II (72.0 ± 6.6) 
           P  0.177 
Glucose DD ( 202.6 ± 73.7) 
ID (189.8 ± 61.3) 
II ( 139.9± 35.2 ) 
    P  0.061 
DD (237.8 ± 66.2) 
ID (180.2 ± 57.5)  
II (184.6 ± 108.2) 
  P*  0.012 
DD (214.4 ± 58.9) 
ID (177.8 ± 60.1) 
II (157.2 ± 61.6) 
         P*    0.038 
Cholesterol DD ( 206.15 47.532 ) 
ID ( 183.00 62.761 ) 
II ( 166.50 35.765 ) 
   P  0.065 
DD (200.6 ± 42.6) 
ID (184.3 ± 53.3) 
II (147.8 ± 56) 
 P*  0.008 
DD (201.9 ± 53.0) 
ID (187.4 ± 54.8) 
II (165.7 ± 33.5) 
           P  0 .195 
Triglycerol DD ( 185.8 ± 161.1 ) 
ID ( 155.7 ± 58.2 ) 
II ( 137.3 ± 62.9 ) 
   P 0.557 
DD(179.2 ± 100.5) 
ID (145.9 ± 49.3) 
II (120.6 ± 65.3) 
  P  0.101 
DD(172.0 ± 115.8) 
ID (150.6 ± 50.9) 
II (139.4 ± 59.2)  
           P   0.609 
Creatinine DD (0 .7 ± 0.3 ) 
ID ( 0.71 ± 0.2 ) 
II ( 0.8 ± 0.16 )     
 P  0.762 
DD (0.7 ± 0.3) 
ID (0.7 ± 0.2) 
II (0.8 ± 0.8) 
  P  0.869 
DD (0.7 ± 0.2) 
ID (0.8 ± 0.2) 
II (0.8 ±0.2) 
            P   0.856 
Urea DD ( 26.6 ± 8 ) 
ID ( 19.1 ± 7.6 ) 
II ( 18.5 ±5.1 )  
   P٭0.001 
DD (22.4 ± 8.6) 
ID (17.2 ± 5.8) 
II (16.3 ± 6.2) 
  P*   0.018 
DD (25.6 ± 7.3) 
ID (18.4 ± 6.2) 
II (19.1± 5.0) 
            P*  0.004 
eGFR DD ( 115.8 ± 27.5 ) 
ID ( 119.8 ± 15.9 ) 
II ( 122.1 ± 19.7 ) 
  P   0.729 
DD (122.2 ± 25.3) 
ID (118.312 ± 11) 
II (133.4 ± 33.9) 
  P  0.271 
DD (114.3 ± 27.4) 
ID (115.6 ± 20.1) 
II (123.8 ± 19.1) 
           P    0.593 
Diabetic 
duration 
DD (7.6 ± 4.5) 
ID (7.07 ± 3.8) 
II (7.3 ± 3.5) 
  P   0.909 
DD (7.5 ± 4.7) 
ID (8.9 ± 4.3) 
II (7.5 ± 3.2) 
  P   0.506 
DD (6.7 ± 3.9) 
ID (8.4 ± 3.7) 
II (6.6 ± 3.9) 
  P   0 .376 
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6. DISCUSSION 
Type 2 diabetes mellitus is a metabolic disorder of chronic disease that leads to the development 
of micro and macrovascular complications such as DR, DN, diabetic neuropathy and 
cardiovascular disease (Tesfaye & Gill, 2011; Al-Khawlani et al., 2010 and Michael, 2008). 
Hypertension is the most common risk factor of diabetes mellitus. Genetic or non-genetic factors 
are able to predispose to diabetes and facilitate the progress of diabetic complications, as 
reported by different authors (Vivian et al., 2010; Holt, 2004 and Strojek et al., 1997). The non-
genetic risk factors such as BMI, age (oldest age), life style, smoking, dyslipidemia, and 
environmental factors are the most common risk factors for T2DM,  diabetic complications and 
diabetic hypertentions (Viswanathan et al., 2012; Bakris,  2011; Roaeid and Kadiki. 2011; Haque 
et al., 2010 and  Hribal et al., 2002). There are many candidate genetic variants associated to the 
occurrence of T2DM (Singh, 2011). However, genes of the RAAS such as renin, 
angiotensinogen (AGT), angiotensin-1 converting enzyme (ACE), angiotensin converting enzyme 
2 (ACE2), aldosterone synthase (CYP11B2), angiotensin II type 1(AT1R) and type 2 (AT2R) 
receptors all of these genes or genetic loci responsible for excess Ang II production and Ang II 
has the most common physiological effect on T2DM, diabetic complication and diabetic 
hypertension (Hsueh and Wyne, 2011 and Zhou and Schulman, 2009).   
The ACE I/D polymorphism has a potential link to diabetes and able to assist the  progross of 
diabetes to microvascular complications, macrovascular complications and hypertention (Saleem 
et al., 2015; Zhou et al., 2013 and Schmidt et al., 1995). However, the ACE gene polymorphism 
and risk of T2DM has conflicting reports. In this study, ACE gene polymorphism and associated 
risk factors in patients with T2DM, diabetic complication and diabetic hypertension with a 
healthy control group were studied. It was found that the frequency of DD genotype as well as D 
allele has shown statistically significant increase in diabetic patients in comparison to healthy 
control groups (64.2% and 79.3% Vs 35.6 and 59.9% P < 0.001) respectively as shown in Table 
3 and Figure 4.  DD genotype carriers have shown more than twofold increased risk of 
developing T2DM as compared to II genotype carriers (OR: 2.984, CI: 1.332 - 6.689, P < 0.02). 
D allele was five times higher than I allele associated to diabetic patients than healthy controls 
(OR, D 2.178; CI: 1.168 – 3.232 P < 0.001 Vs I OR, 0.459; CI: 0.309 – 0.681 P < 0.001). This 
finding is in agreement with some other studies, which indicated DD genotype is associated with 
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high increased risk of T2DM and D allele has high relative risk towards developing type 2 
diabetes mellitus (Ali-Bahar et al., 2014; Zarouk et al., 2009; Nikzamir et al., 2008; Yang et al., 
2006; Stephens et al., 2005; Ergen et al., 2004 and Hsieh et al., 2000) and while others reported  
that there was no association between ACE DD genotype and T2DM (Choudhry et al., 2012; 
Chmaisse et al., 2009 and Degirmenci et al., 2005). The risk factors such as mean SBP, DBP, 
total cholesterol (TC), triglycerol (TG), fasting blood glucose (FBG), creatinine and urea (P < 
0.001), and BMI (P < 0.05) has shown statistically significant difference in cases as compared to 
healthy control groups (Table 1). This is similarity with other studies where SBP, DBP, TC, TG, 
FBG level, creatinine and urea contents showed statistically significant association to T2DM 
patients than healthy control study groups (Nikzamir et al., 2008; Yang et al., 2006 and Ergen et 
al., 2004). The study in Brazil is also similar with the current study indicated that FBG, 
dyslipidemia (TC and TG) are highly prevalence in T2DM patients (Carolino et al., 2008). 
Whenever the genotype distribution and these clinical parameters were compared, there were 
statistically significant association between the DD genotype holders and the amount of SBP, 
TC, TG and urea (P < 0.001), DBP (P < 0.01), and BMI (P < 0.02) among T2DM patients 
compared to healthy control groups having the same genotype holders (Table 4). This is disagree 
with some other reports by Choudhry et al., (2012); Degirmenci et al., (2005) and Hsieh et al., 
(2000) indicated that clinical characteristic of T2DM patients such as age, BMI, SBP, DBP, 
hemoglobin A1C (HbA1C), TC, TG, HDL cholesterol levels, duration of diabetes, FBG and 
random blood sugar (RBS) level according to ACE I/D genotypes are no significance difference 
(Choudhry et al., 2012; Degirmenci et al., 2005 and Hsieh et al., 2000). Similarly the study in 
USA showed that BMI, waist, fat-free mass, and physical activity did not differ by ACE 
genotype (Bonnet et al., 2008). On the other hand, in this study some of the clinical variables 
such as age, FBG, creatinine and eGFR did not showed statistically significant association 
towards ACE genotype holders between study case groups and healthy controls (Table 4). This is 
harmony with the study in USA, age and fasting glucose are not associated with ACE gene 
polymorphism, but 2-h glucose levels are higher in DD than ID and II subjects of T2DM (Bonnet 
et al., 2008). Cigarette smoking is a risk factor for T2DM, diabetic complications and DD 
genotype are greater risk (Sairenchi et al.,2004). However, in this study there were no any cases 
that are smoking cigarettes.  
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Whenever the associations of ACE gene polymorphism with type 2 diabetic hypertension 
patients were evaluated, in this study there were existed statistically significant association 
between DD genotype and type 2 diabetic hypertension patients (41.6% Vs 19.5%) Table 5 and 
Figure 5. This is in agreement with the previous study conducted in a south Indian population 
(Anbazhagan et al., 2009), in south china population (Jiang et al., 2009), in Malaysian 
population (Ramachandran et al., 2008) and in Iranian population (Nakhjavani et al., 2007) 
which have indicated the existence of statistically significant association between the DD 
genotype and D allele among diabetic hypertension patients whereas others did not found a 
positive correlation between the DD genotype of ACE gene polymorphism and diabetic 
hypertension patients (Tascilar et al., 2009 and Chuang et al., 1997). Another study conducted 
on Turkish population also indicated no significant association between ACE gene 
polymorphism and hypertension (Gunes et al., 2004). This variation is may be due to ethnic 
factors (Saab et al., 2007) and environmental background (Ono et al., 2003). Among the 
clinical/biochemical risk factors, including SBP (P < 0.001), DBP (P < 0.01), age and urea (P < 
0.05) were significantly associated in diabetic hypertension patients compared with T2DM 
patients. This is in agreement with other reports found that age and SBP is high in the affected 
population (Alsafar et al., 2015 and Roaeid and Kadiki, 2011). The other risk factors including 
BMI, TC, TG, creatinine, FBG and duration of diabetes were no significance association in 
diabetic hypertension compared with T2DM. This is in agreement with the studies by 
Ramachandran et al., (2008) and Nakhjavani et al., (2007) indicated that BMI, TC, TG, LDL, 
HDL and FBG level are no significance difference between type 2 diabetic hypertension and 
T2DM (Ramachandran et al., 2008 and Nakhjavani et al., 2007). The other report also indicated 
that BMI and TC are no significance variation between diabetic hypertension and non diabetic 
hypertension group (Mengesha, 2007). On the other hand, the present finding  is dissimilar with 
other reports found that TG, creatinine and duration of diabetes are associated with type 2 
diabetic hypertension compared to non hypertension T2DM (Mengesha, 2007 and Nakhjavani et 
al., 2007). When comparing the association of risk factors and ACE gene polymorphism; DD 
genotypes of diabetic hypertension patients were highly affected by SBP, DBP and age 
compared with T2DM patients. This result is in agreement with other study, which showed 
diabetic patients >50 years of age have had double risk of developing diabetic complication than 
younger counter parts < 50) (Roaeid and Kadiki, 2011). While other risk factors in the present 
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study such as BMI, TC, TG, FBG, creatinine and urea regarding to ACE gene polymorphism did 
not show significance variation between diabetic hypertension and T2DM. This is dissimilar 
with the report of Zhou et al. (2013) found that TG level is higher in the ID and DD genotype 
than II genotype carriers, but level of FBG is similar with the present finding indicated that FBG 
level had no different on ACE gene polymorphism between type 2 diabetic and diabetic 
hypertension (Zhou et al. 2013).  
Regarding to diabetic retinopathy, Angiotensin II gene has been reported to play a role in the 
progress of retinopathy by stimulation of growth factors such as vascular endothelial growth 
factor, platelet-derived growth factor and connective tissue growth factor (Wilkinson-Berka., 
2006). In the present study, the frequency of DD genotype was high in diabetic retinopathy 
patients when computed against T2DM patients without complications (28.6% Vs 19.5%) as 
shown in Table 5 and Figure 5. This result is in complete harmony with other similar studies 
conducted elsewhere like in Turkey, where DD genotype was an independent risk factor in DR 
patients (Kutluturk et al., 2014), and in Chaina, a Meta analysis study; DD genotypes increase 
the risk of developing DR (Lu et al., 2012 ). While the other report in china indicated that ACE 
gene polymorphism has no difference in diabetic retinopathy patients (Khan et al., 2015). On the 
other hand the recent report in Pakistan opposed the present study and indicated that ID genotype 
individuals are at risk for DR (Saleem et al., 2015). Whenever in the present study the role of 
two genotypes (ID and II) of ACE gene polymorphism were analyzed towards risk of DR among 
T2DM patients, they did not show significant association. The clinical/biochemical 
characteristics glucose (P < 0.014) and urea (P < 0.004) were associated in DR patients as 
compared to T2DM shown in Table 2. This result is dissimilar with reports from China; fasting 
plasma glucose has no significant difference between DR and diabetic non retinopathy groups 
(DNR), but blood urea nitrogen is associated with DR than in DNR group (Meng et al., 2015). 
Other clinical/biochemical characteristics such as gender, age, BMI, SBP, DBP, creatinine, 
eGFR, total cholesterol and triglycerol did not show statistically significant association in DR 
patients as compared to T2DM shown in Table 2. This is harmony with the report of Meng et al., 
(2015) showed that age, BMI and triglycerol no statistically significant differences between the 
DR and DNR groups (Meng et al., 2015). However, the other studies shown a significant 
association of BMI, SBP, triglycerides cholesterol, total cholesterol and duration of diabetes in 
patients with DR (Meng et al., 2015; Rani et al., 2009 and Al-Shammari et al., 2005).   When the 
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genotype distribution and these clinical parameters were compared, there were statistically 
significant association between the DD genotype holders and the amount of glucose, total 
cholesterol and urea in DR patients compared with DNR patients with the same genotype 
holders. This is in agreement with other report; high total cholesterol is associated risk factor for 
the development of DR (Hussain et al., 2013). While, the other parameters did not show 
statistically significant association towards DD genotype holders between DR and T2DM 
patients Table 7. 
 In diabetic nephropathy, Sample size was not enough in patients having DN, to assess the 
association of clinical characteristics and ACE gene polymorphism with the severity of 
nephropathy in the current study. This is not surprise, because, similarly the report in the 
northern part of Ethiopia, diabetic clinic at Mekelle Hospital indicated that among 105 diabetic 
patients only 2% of them had diabetic nephropathy (Gill et al., 2008). However, within the 
existing sample size of the current study, the risk factors including SBP (P < 0.05), creatinine (P 
< 0.01) and eGFR (P < 0.01) were associated with DN patients. This result is harmony with 
other reports showed that high blood pressure (BP) associated with DN is known to worsen renal 
function, that initiate and accelerate DN When a patient develops persistent proteinuria and 
elevated arterial BP, kidney function starts to decline as a result of decreased  eGFR among 
progressors with elevated SBP compared to non progressors (Viswanathan et al., 2012). Serum 
creatinine is a risk factor among progressors DN compared to non-progressors of T2DM which 
leads to the occurrence of DN (Viswanathan et al., 2012). Similarly another study revealed that 
elevated BP, SBP but not DBP was a risk factor for the development of diabetic nephropathy 
(Kasper et al., 2004). The other studies also indicated that SBP, creatinine and eGFR are 
associated with the development of diabetic nephropathy (Fontela et al., 2014, Shlomo et al., 
2011 and Degirmenci et al., 2005). However, these risk factors did not associated with ACE gene 
polymorphism in DN patients. On the other hand, risk factors such as glucose and urea has 
statistically significant association with DD genotype of DN patients (DD: 214.4 ± 58.9, ID: 
177.8 ± 60.1 and II: 157.2 ± 61.6 P < 0.05) and (DD: 25.6 ± 7.3, ID: 18.4 ± 6.2 and II 19.1± 5.0 
P < 0.01) respectively. This is similar with the study in Austria; poor glycemic control is 
associated with ACE-D allele, a major risk factor for the development of diabetic nephropathy 
(Barnas et al., 1997). The other study also indicated that fasting glucose, post-prandial glucose 
levels and serum urea are higher in progressors of diabetic kidney complication compared to 
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non-progressors of T2DM patients (Viswanathan et al., 2012). On the other hand, blood glucose 
has no direct effect upon kidney disease but has an indirect effect through serum creatinine 
(Ahmad et al., 2014). The other risk factors such as age, TC and TG were not associated with 
DN either independently as a risk factor or associated with ACE gene polymorphism. This is 
harmony with other studies age, serum total cholesterol and LDL cholesterol are not associated 
with diabetic nephropathy ( Shen et al., 2008). However, TG is an independent risk factor for 
diabetic nephropathy ( Shen et al., 2008). 
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7. CONCLUSION 
In conclusion, the present study indicated that ACE gene of DD genotype and D allele have been 
associated with high risk of diabetes and diabetic complications in diabetes patients (OR:DD 
2.984, CI: 1.332 - 6.689, P < 0.02 and D 2.178; CI: 1.168 – 3.232 P < 0.001 Vs I, 0.459; CI: 
0.309 – 0.681 P < 0.00). Moreover, this genotype and allele was associated with some of the 
clinical Parameters such as age, SBP, DBP, glucose, total cholesterol and urea. Type 2 diabetes 
mellitus patients having DD genotype have had high relative risk of getting diabetic 
complication as compared to ID and II genotype holders. The frequency of DD genotype was 
high in diabetic hypertension and diabetic retinopathy patients than T2DM without complication 
and diabetic nephropathy. The genotype (ID and II) and I allele in the healthy control group were 
high as compared to the cases. Similarly, ID and II genotype in the study subjects (cases) had 
less risk of developing diabetic complications as compared to cases with the DD genotype.  
Some of the associated risk factors, DD genotype and both risk factors and DD genotype were 
associated to T2DM and its complications, which indicates the need for doing a similar study 
with a larger sample size to unravel the independent associated risk factors and ACE gene 
between T2DM and diabetic complication. 
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8. LIMITATIONS OF THE STUDY 
This study has some limitations:  
Sample size was not enough in patients having diabetic nephropathy, to assess the relation of 
clinical characteristics and ACE gene polymorphism with the severity of nephropathy. The assay 
for LDL and HDL could not done, those tests could have given a better estimate of lipoproteins. 
The tests were used only one primer for the detection ACE genotype I/D, it is better to use a 
second primer after electrophoresis to increase the specificity of DD genotyping.  
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9. RECOMMENDATIONS 
Based on the present result of this study the following recommendations are forwarded  
 Early diagnosis is very much essential for better treatment out come and avoid 
complications, thus it is advisable to the general population to conduct periodic diabetic 
test. Because during sample collection from healthy control groups, 5 individuals had 
hypertension and 9 individuals had hyperglycemia 
 To use DD genotype as a marker for risk of Diabetic similar studies on the same and 
different population are warranted with large sample size. 
 However, depending on the present finding all diabetes patients are best treated with ACE 
inhibitor drugs to prevent the progress of diabetes individuals for further diabetic 
complication. 
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APPENDIX 
 
   Appendix 1 Consent form 
I, the undersigned (full name) -----------------------------------------------------------------who is 
living at --------------Zone, wereda-------------- kebele ---------- and urban/rural ---------------------- 
willingly agree to provide 5ml of my blood sample for the principal investigator of this project. 
The investigator should ethically bind and use this blood sample only for the said research and 
will completely be responsible if they don’t keep the result and status of the sample confidential. 
Name and signature of the participant                                                                          date 
-------------------------------------------------------                                                       ------------------- 
        Appendix 2 Questionnaire for associated risk factors for all diabetes patients 
 
                                  Demographic information 
Question  Response  
1 Sex (record male/ female as observed) Male ,       female 
2 How old are you? Years --------------- 
             Behavioral measurements  
6 Do you smoke any tobacco product? Such as cigarettes, 
cigars or pipes? 
Yes         
No 
7 Do you currently smoke tobacco daily? This question is 
only for current smoker of tobacco product. 
 
Age( years)------- 
8  
How old were you first started smoking daily? 
 
Age(years)------------- 
9 On average, how many cigarettes per day do you use? ------------------- 
10 Did someone smoke in closed areas in your work 
place?(in the building, in a work area or a specific office) 
 
Yes       No 
11 In question 10 if the answer is Yes asked as how many 
days did someone smoke in closed areas in your work 
place? 
Number of days ----- 
Don’t know 
Work in a closed 
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                     History of diabetes 
1 How old are you? (you age 1st diagnosis) When you ever 
been told by a doctor or other health worker that you have 
raised blood sugar or diabetes? 
 
Age (years)-------- 
2 Are (were) any family member suffering from DM 
disease? 
Yes 
No  
3 Are (were) you suffering from other disease? Like kidney, 
retinopathy, hypertension and neuropathy. 
Yes  
No  
4 Does the doctor told you; other disease are due  to 
diabetic? 
Yes   
No  
5 How old are you?(you age 1st diagnosis with other 
disease) 
 
Age(year)---------- 
6 Are (were) any family member suffering from other 
disease? Like kidney, retinopathy, hypertension and 
neuropathy 
Yes 
No  
                           Physical measurement  
1 Height (in cm) In centimeter --------------- 
2 Weight (in kg) In kilogram------------------- 
3  
Blood pressure-record three heart rate readings 
 
SBP/ DBP (mmHg) 
 1.-----------2.-------- 3.------- 
Average-------------beats per 
minute 
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Appendix 3 P value   of clinical characteristics between T2DM and Control 
 
 
 
Group Statistics 
 Status of the 
study 
participants N Mean Std. Deviation Std. Error Mean 
Gender T2DM 111 .50 .502 .048 
Controls 111 .48 .502 .048 
systolic T2DM 111 133.66 19.504 1.851 
Controls 111 121.26 6.891 .654 
diastolic T2DM 111 82.61 13.571 1.288 
Controls 111 76.44 5.452 .517 
BMI3 T2DM 111 24.915 4.3862 .4163 
Controls 111 23.604 5.4189 .5143 
glucose T2DM 111 206.37 72.398 6.872 
Controls 111 78.23 15.672 1.488 
cholestrol T2DM 111 194.16 47.871 4.544 
Controls 111 130.47 48.934 4.645 
triglycerol T2DM 111 177.54 135.330 12.845 
Controls 111 99.67 56.761 5.387 
ceratinine T2DM 111 .720 .2484 .0236 
Controls 111 .642 .1899 .0180 
Urea T2DM 111 22.23 8.326 .790 
Controls 111 18.77 4.600 .437 
EGFR T2DM 111 118.411 27.1582 2.5777 
Controls 111 124.702 20.2433 1.9214 
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Appendix 4 P value   of clinical characteristics between T2DM and Control 
Age T2DM 111 54.70 12.340 1.171 
Controls 111 54.27 14.425 1.369 
 
 
     
                                                Independent Samples Test 
  Levene's Test for 
Equality of 
Variances t-test for Equality of Means 
  
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Differenc
e 
Std. Error 
Difference 
95% Confidence Interval 
of the Difference 
  Lower Upper 
Gender Equal variances 
assumed 
.198 .657 .267 220 .789 .018 .067 -.115 .151 
Equal variances 
not assumed 
  
.267 220.000 .789 .018 .067 -.115 .151 
systolic Equal variances 
assumed 
63.869 .000 6.314 220 .000 12.396 1.963 8.527 16.266 
Equal variances 
not assumed 
  
6.314 137.041 .000 12.396 1.963 8.514 16.279 
diastolic Equal variances 
assumed 
79.461 .000 4.446 220 .000 6.171 1.388 3.435 8.907 
Equal variances 
not assumed 
  
4.446 144.603 .000 6.171 1.388 3.428 8.915 
BMI3 Equal variances 
assumed 
.043 .835 1.980 220 .049 1.3101 .6617 .0060 2.6142 
Equal variances 
not assumed 
  
1.980 210.849 .049 1.3101 .6617 .0057 2.6145 
glucose Equal variances 
assumed 
152.816 .000 18.225 220 .000 128.135 7.031 114.279 141.992 
Equal variances 
not assumed 
  
18.225 120.287 .000 128.135 7.031 114.215 142.055 
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Appendix 5 Chi-Square ACE genotype distribution between type 2 diabetic and control. 
Genotype result * Status of the study participants Crosstabulation 
   Status of the study participants 
Total    T2DM Controls 
Genotype 
result 
Homozygous 
Deletion 
Count 77 43 120 
% within Genotype 
result 
64.2% 35.8% 100.0% 
% within Status of the 
study participants 
69.4% 38.7% 54.1% 
cholestrol Equal variances 
assumed 
.000 .983 9.803 220 .000 63.694 6.497 50.888 76.499 
Equal variances 
not assumed 
  
9.803 219.894 .000 63.694 6.497 50.888 76.499 
triglycerol Equal variances 
assumed 
13.623 .000 5.591 220 .000 77.874 13.929 50.422 105.325 
Equal variances 
not assumed 
  
5.591 147.540 .000 77.874 13.929 50.348 105.400 
ceratinine Equal variances 
assumed 
1.234 .268 2.610 220 .010 .0775 .0297 .0190 .1360 
Equal variances 
not assumed 
  
2.610 205.858 .010 .0775 .0297 .0190 .1360 
Urea Equal variances 
assumed 
43.732 .000 3.832 220 .000 3.459 .903 1.680 5.239 
Equal variances 
not assumed 
  
3.832 171.421 .000 3.459 .903 1.677 5.242 
EGFR Equal variances 
assumed 
3.167 .077 -1.956 220 .052 -6.2902 3.2151 -12.6265 .0460 
Equal variances 
not assumed 
  
-1.956 203.400 .052 -6.2902 3.2151 -12.6293 .0489 
Age Equal variances 
assumed 
2.604 .108 .240 220 .811 .432 1.802 -3.119 3.983 
Equal variances 
not assumed 
 
.657 .240 214.851 .811 .432 1.802 -3.119 3.984 
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% of Total 34.7% 19.4% 54.1% 
Hetrozygous 
Insertion-deletion 
Count 22 48 70 
% within Genotype 
result 
31.4% 68.6% 100.0% 
% within Status of the 
study participants 
19.8% 43.2% 31.5% 
% of Total 9.9% 21.6% 31.5% 
Homozygous 
Insertion 
Count 12 20 32 
% within Genotype 
result 
37.5% 62.5% 100.0% 
% within Status of the 
study participants 
10.8% 18.0% 14.4% 
% of Total 5.4% 9.0% 14.4% 
 
Total 
Count 111 111 222 
% within Genotype 
result 
50.0% 50.0% 100.0% 
% within Status of the 
study participants 
100.0% 100.0% 100.0% 
% of Total 50.0% 50.0% 100.0% 
 
Appendix 6 Chi-Square ACE genotype P value between T2DM and Control 
Chi-Square Tests 
 
Value Df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 21.290
a
 2 .000 
Likelihood Ratio 21.680 2 .000 
N of Valid Cases 222   
a. 0 cells (.0%) have expected count less than 5. The minimum expected 
count is 16.00. 
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Appendix 7 Chi-Square ACE genotype distribution among type 2 diabetic 
Complications. 
Genotype result * Status of the study participants Crosstabulation 
   Status of the study participants 
Total 
   
T2DM 
t2dm with 
hypertention 
t2dm with 
retinopathy 
t2dm with 
nephropathy 
Genotype 
result 
DD Homozygous 
Deletion 
Count 15 32 22 8 77 
% within 
Genotype result 
19.5% 41.6% 28.6% 10.4% 100.0% 
% within Status of 
the study 
participants 
42.9% 91.4% 73.3% 72.7% 69.4% 
% of Total 13.5% 28.8% 19.8% 7.2% 69.4% 
ID Hetrozygous 
Insertion-deletion 
Count 12 3 5 2 22 
% within Genotype 
result 
54.5% 13.6% 22.7% 9.1% 100.0% 
% within Status of 
the study 
participants 
34.3% 8.6% 16.7% 18.2% 19.8% 
% of Total 10.8% 2.7% 4.5% 1.8% 19.8% 
II Homozygous 
Insertion 
Count 8 0 3 1 12 
% within Genotype 
result 
66.7% .0% 25.0% 8.3% 100.0% 
% within Status of 
the study 
participants 
22.9% .0% 10.0% 9.1% 10.8% 
% of Total 7.2% .0% 2.7% .9% 10.8% 
Total Count 35 35 30 11 111 
% within Genotype 
result 
31.5% 31.5% 27.0% 9.9% 100.0% 
% within Status of 
the study 
participants 
100.0% 100.0% 100.0% 100.0% 100.0% 
% of Total 31.5% 31.5% 27.0% 9.9% 100.0% 
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Appendix 8  Chi-Square ACE genotype P value between T2DM and Control. 
 
 
 
 
 
 
 
 
Appendix 9 Multivariate logistic regression of genotypes among type 2 diabetes and 
control. 
 
Appendix 10 logistic regression of I/D allele among type 2 diabetes and control. 
Variables in the Equation 
  
B S.E. Wald df Sig. Exp(B) 
95.0% C.I.for EXP(B) 
  Lower Upper 
Step 1
a
 D .778 .201 14.945 1 .000 2.178 1.468 3.232 
Constant -1.094 .320 11.689 1 .001 .335   
a. Variable(s) entered on step 1: D.       
 
Chi-Square Tests 
 
Value Df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 20.713
a
 6 .002 
Likelihood Ratio 23.636 6 .001 
N of Valid Cases 111   
a. 5 cells (41.7%) have expected count less than 5. The minimum expected 
count is 1.19. 
 
Parameter Estimates 
Status of the study 
participants
a
 B Std. Error Wald df Sig. Exp(B) 
95% Confidence Interval for Exp(B) 
Lower Bound Upper Bound 
T2DM Intercept -.511 .365 1.957 1 .162    
[genotype=DD] 1.093 .412 7.050 1 .008 2.984 1.332 6.689 
[genotype=ID] -.269 .447 .363 1 .547 .764 .318 1.834 
[genotype=II] 0
b
 . . 0 . . . . 
a. The reference category is: Controls.       
b. This parameter is set to zero because it is redundant.      
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B S.E. Wald df Sig. Exp(B) 
95.0% C.I.for EXP(B) 
  Lower Upper 
Step 1
a
 I -.778 .201 14.945 1 .000 .459 .309 .681 
Constant .463 .180 6.582 1 .010 1.589   
a. Variable(s) entered on step 1: I. 
 
      
Appendix 11: Online calculating formula of eGFR by using CKD-EPI equation. 
CKD-EPI equation calculator should be used when Scr reported in mg/dL. This equation is 
recommended when eGFR values above 60 mL/min/1.73 m2 are desired. 
GFR = 141 × min (Scr /κ, 1)α × max(Scr /κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if 
black]  
where: 
Scr is serum creatinine in mg/dL, 
κ is 0.7 for females and 0.9 for males, 
α is -0.329 for females and -0.411 for males, 
min indicates the minimum of Scr /κ or 1, and 
max indicates the maximum of Scr /κ or 1. 
The equation does not require weight because the results are reported normalized to 1.73 m2 
body surface area, which is an accepted average adult surface area. 
Serum creatinine                     (mg/dL) 
Age*   
African American          Yes             No 
Gender         Male                  Female 
     
GFR value:                     mL/ min/1.73 m2** 
*This equation should only be used for patients 18 and older. 
The National Kidney Disease Epidemiology Program presently recommends reporting estimated 
GFR values greater than or equal to 60 mL/min/1.73 m2 simply as "≥60 mL/min/1.73 m2", not 
an exact number. 
 
 
 
Calculate Clear 
 
